Next Article in Journal
Selenate Prevents Adipogenesis through Induction of Selenoprotein S and Attenuation of Endoplasmic Reticulum Stress
Next Article in Special Issue
Resveratrol-Induced White Adipose Tissue Browning in Obese Mice by Remodeling Fecal Microbiota
Previous Article in Journal
Identification of Epigenetic Mechanisms Involved in the Anti-Asthmatic Effects of Descurainia sophia Seed Extract Based on a Multi-Omics Approach
Previous Article in Special Issue
Phytochemical and Biological Profile of Moricandia arvensis (L.) DC.: An Inhibitor of Pancreatic Lipase
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

Anti-Obesity Effects of Medicinal and Edible Mushrooms

Food Science and Technology Program, Beijing Normal University—Hong Kong Baptist University United International College, 2000, Jintong Road, Tangjiawan, Zhuhai 519087, China
Author to whom correspondence should be addressed.
Molecules 2018, 23(11), 2880;
Submission received: 27 September 2018 / Revised: 29 October 2018 / Accepted: 2 November 2018 / Published: 5 November 2018
(This article belongs to the Special Issue Natural Bioactives in Anti-Obesity Therapy)


Obesity is a group of metabolic disorders caused by multiple factors, including heredity, diet, lifestyle, societal determinants, environment, and infectious agents, which can all lead to the enhancement of storage body fat. Excess visceral fat mass in adipose tissue generate several metabolic disorders, including cardiovascular diseases with chronic inflammation based pathophysiology. The objective of the current review is to summarize the cellular mechanisms of obesity that attenuate by antioxidant potentials of medicinal and edible mushrooms. Studies have showed that mushrooms potentially have antioxidant capacities, which increase the antioxidant defense systems in cells. They boost anti-inflammatory actions and thereby protect against obesity-related hypertension and dyslipidemia. The practice of regular consumption of mushrooms is effective in the treatment of metabolic syndrome, including obesity, and thus could be a good candidate for use in future pharmaceutical or nutraceutical applications.

1. Introduction

Obesity is a group of disorders defined as a body mass index (BMI) of more than 30 kg/m2, in which enhancement of storage body fat deposited in the adipose tissue can cause deleterious health effects. The complications of obesity (e.g., diabetes, cardiovascular diseases (CVD), pulmonary diseases, obstructive sleep apnea, cancer, osteoarthritis etc.) are usually caused by a combination of high food intake, sedentary lifestyles, lack of physical activity and a genetic predisposition. Hence, obesity is a metabolic syndrome that reflects an imbalance between energy intake and expenditure [1,2]. It is measured by excess stored fat and high lipid content in the plasma. The quantity of total mass of fat is enhanced by the availability of adipocytes and proliferation and cell differentiation that results in both augmented number and size of fat cell [1]. Adipose tissue is a significant organ that contributes energy balance in the body. High-fat accumulation causes an unusual progress of white adipose tissue that contributes to obesity in humans [2]. The primary management of obesity involves diet, exercise, and surgical intervention. In addition, there are treatment strategies such as the prevention of high-calorie intake, suppression of appetite, and the therapeutic drugs which affect mobilization and consumption of lipids [3]. Nevertheless, a successful result is also confirmed only in a trivial number of the population. Therapeutic drugs for obesity, such as orlistat (Xenical®) and sibutramine (Reductil), are found to cause many complications that include emesis, insomnia, headache, myocardial infarction, stomach pain and constipation [4]. In the growing medical field, clinicians often face main complications of multiple risk factor syndrome, including diabetes, pulmonary diseases, osteoarticular diseases, CVD (atherosclerosis, elevated blood pressure, stroke, dyslipidemia) and some of the commonest forms of cancer [5]. These can lead to morbidity and mortality in which obesity is the foremost cause of these syndromes.

2. Etiology of Obesity

A combination of excess nutrients and a lack of physical activity is the primary causative factor in most cases of obesity. In addition, obesity is caused by hereditary, medications or mental illness and endocrine disorders [6]. Sometimes high proportions of obesity are seen at a communal level and persist due to readily accessible tastier food, changes the mode of transportation, and increasing urbanization [7]. Further studies have shown that some of the potential contributors to elevated obesity levels include hormonal disruptors, inadequate sleep, the variability of ambient temperature, smoking habits, cravings, usage of medications (e.g., antipsychotic drugs), pregnancy at a later age, inherited risk factors and elevated BMI [8,9].

2.1. Diet, Lifestyle, and Societal Determinants

The global rate of obesity increased more than threefold between 1980 and 2014. More than 600 million people were considered obese in 2014. Almost 40 percent of men and women 18 years old and above were overweight. Over 41 million children (<5 years old) were overweight or obese in Asia. It is predicted that 1.12 billion people will be obese around the world in 2030 [10]. In most of the developed countries people die due to their overweight condition and obesity. This scenario is also rising in lower-middle-income nations, mostly in urban backgrounds. Overweight or obesity rates in Africa (1990–2014) increased by nearly double from 5.4 million to 10.6 million [11]. Overweight is mostly caused by the consumption of energy-dense foods when the ingestion of carbohydrates is higher than in a fat diet [12]. In addition, the lack of physical activity highly influences the rate of enhancement of obesity. Presently, over ¾ of the global population is found to exercise inadequately, along with the increasing sedentary nature of daily tasks, laborsaving technology, altered modes of transportation, and increasing urbanization. There is an increasing relationship between television watching time and obesity threat in both adults and children [13]. WHO further specified global populations are being less active in leisure pursuits, environmental and societal alterations connected with the progress and deficiency of encouraging strategies in various sectors including education, health, urban planning, farming, transport, environment, food, and advertising [10]. In developed nation’s populations, those with higher incomes are more probable to have obesity than those with low income. No significant relation is seen between obesity and education in men. Nevertheless, higher income women have less obesity than low-income women. Furthermore, women with college degrees are less probable to have obesity compared with less educated women [12]. Smoking is another societal factor that influences overweight. Over ten years, those who quit smoking will increase in weight by 4.5 kg (men), and 5.0 kg (women), respectively [14].

2.2. Genetics

More than 70 percent of obesity is caused by heredity. This is a consequence of phenotypes, which are linked to adipose tissue distribution and excess body fat [2]. Excessive adiposity and increase with age are also influenced by heredity. According to Neel’s ‘thrifty gene’ hypothesis, genes that predispose to obesity in populations that often experienced hunger [15]. Individuals who possess these genes develop the ‘obesogenic’ environment and can become extremely obese. Nowadays, this is predominantly seen in Pima Indians and Pacific Islanders [15]. Many genes involved in glucose and lipid metabolism are subject to positive selection in Asian and African ethnic groups. The search for genes that enhance the vulnerability to improve obesity has become progressively significant. There have been several studies that have proved that the candidate genes are extremely associated with obesity and elevated body weight [11].

2.3. Medical and Psychiatric Illness

Numerous psychiatric prescriptions are recognized as weight gain agents that cause obesity in most psychiatric cases [16]. Weight gain is connected with the use of mood stabilizers (lithium, valproate), antipsychotics (clozapine and olanzapine), and antidepressants (amitriptyline), which may have serious long-term complications [17]. Medical sicknesses that threaten to augment obesity include congenital (hypothyroidism, dwarfism, cretinism) or genetic syndromes (Cohen syndrome), and night eating syndrome [18]. The menace of obesity is significantly higher in psychiatric patients than in patients with non-psychiatric complaints and these adverse effects of medications vary with age and sex [19].

2.4. Infectious Agents

The term “infectobesity” describes obesity of infectious origin. Infectious agents, especially viruses, have been identified to cause obesity in various animal models [20]. Human Adv36 can induce insulin sensitivity, obesity, and hepatic steatosis in chickens, mice, and monkeys. Canine distemper virus and avian adenovirus were reported to cause growth failure, fatty liver, and obesity in mice. An avian retrovirus (Rous-associated virus-7) in chicken, and Borna disease virus in rats caused neuronal degeneration in the brain, obesity, hyperuricemia, and dyslipidemia. Scrapie agents were also reported to induce obesity in mice and hamsters [20]. Infections may not be completely associated with obesity as a causal factor; however, there may be a connection to the consequences of obesity [21]. It has found that overweight individuals are highly vulnerable to several types of contagion, due to the weakening of the immune system. Moreover, in severe obesity cases, the course of infectious diseases is more severe [20].

3. Pathophysiology of Obesity

Hormones like leptin and ghrelin are internal mediators in humans involved in feeding and hunger. Leptin is a peptide hormone synthesized by adipocytes, which play a key role in the storage of fat in the body, and regulates long-standing appetite. When the energy reserves are adequate, leptin levels are increased and this would suppress further food ingestion. It is formed by the ‘ob’ gene in mice [22]. Ghrelin is another peptide hormone synthesized by the fundus lining of the stomach and epsilon cells of the pancreas, which regulates temporary appetite control. This peptide hormone plays a chief function in the maintenance of energy balance and body weight by impeding food ingestion and elevating energy expenditure through the hypothalamus [23]. Administration of leptin could be a powerful treatment in obese, mainly leptin deficient, individuals. A majority of obese persons are identified as leptin resistant and have been identified as having elevated leptin concentrations in their blood [24]. Leptin resistance in overweight individuals, which is due to the extreme synthesis of leptin with ineffective appetite control, is very common [22]. Although both leptin and ghrelin are synthesized peripherally, they regulate cravings through the hypothalamus, which regulates the intake of food and energy expenditure. The pro-opiomelanocortin (POMC) pathway in the hypothalamus is the significant circuit that stimulates satiety and inhibit feeding. It is initiated by an arcuate nucleus, lateral and ventromedial hypothalamus. The arcuate nucleus has another two functional neuron units, namely neuropeptide Y (NPY) and agouti-related peptide (AgRP) that provoke responses in the hypothalamus. Both induce feeding and inhibit satiety. Both units of the arcuate nucleus are mediated by leptin and ghrelin. These hormones inhibit the NPY/AgRP group while eliciting the POMC group and vice versa. Therefore, a deficiency of leptin signaling either via lacking leptin or leptin resistance encourages to overeating and ultimately causes some heritable and acquired types of obesity [22] (Figure 1).

4. Pathologies Associated with Obesity and Its Effects on Health

Obesity is an amplification of normal adiposity and is a central dogma in the pathophysiology of diabetes, cancer, dyslipidemia, hypertension, and atherosclerosis. It largely affects health because of the secretion of excessive adipokines [22,23]. Obesity is a key agent in metabolic malfunctions involving lipid and glucose metabolism and influences organ dysfunction involving the heart, liver, intestines, lungs, hormones, and reproductive functions. Obesity is coupled with numerous pathological effects due to the extra body weight (i.e., worsening of osteoarthritis, sleep apnea, gout, and pain of the vertebral column) [15,22]. Moreover, obesity is highly connected to the following occurrence and pathologies.

4.1. Chronic Inflammation and Endothelial Dysfunction

Over one billion adipocytes are present in humans, where they have the functions of storage of triglycerides in fat depots and supplying energy. In addition, they act as a major endocrine organ that regulates adipocyte hormones like leptin, adiponectin, and visfatin. Accompanying pancreatic hormones (insulin), these adipocyte hormones help normalize body-fat mass [25]. These body fat depots release inflammatory adipokines including cytokines (TNF-α, IL-1, and IL-6), complement proteins and growth factors, which generate local steatonecrosis in the vascular system and cause inflammation and endothelial dysfunction [25]. Studies have also demonstrated that the biomarkers of inflammation and endothelial dysfunction are connected with CVD, atherosclerosis, hypertension, and insulin resistance [26].

4.2. Hypertension and Atherosclerosis

The incidence of hypertension and atherosclerosis are substantially higher in individuals with obesity (>60%) which affects different proportions of men (78%) and women (64%) [27]. The occurrence of hypertension enhances BMI dependence in both genders with increasing age [28]. Obesity affects individuals progressively, and later leads to morbidity and mortality. The incorporation of obesity, hypertension, and atherosclerosis has two key complications [29]. Initially, this combination is most dangerous for patients with obesity and high blood pressure that have elevated incidence of CVD, including coronary artery disease, carditis, cardiomyopathy, cardiac arrhythmia, end-stage renal disease, stroke, and obstructive sleep apnea [30]. Furthermore, obesity enhances the threat of treatment-resistant arterial blood pressure; as a result, several medications and equipment therapy like renal sympathetic denervation are needed [31]. Hormonal studies of the adipose tissue also found a connection between obesity, atherosclerosis, and hypertension, likely to cause adiposity dysfunction due to excess secretion of bioactive molecules and immunomodulators [32]. The impairment of adiposity in individuals with obesity causes insulin resistance, malfunctioning in the renin-angiotensin-aldosterone system as well as the sympathetic and parasympathetic nervous system [33]. These hormones are important to regulate the structure and functions of the kidney (Figure 2).
Obesity can cause an upsurge in the risk of endometrial cancer through endocrine pathways. Obesity is related with augmented insulin levels, which may lead to elevated insulin-like growth factor 1 and synthesis of androgens that ultimately cause progesterone deficiency [27]. Lack of progesterone progresses to cause anovulation and consequently appears to be the most significant physiological risk factor for endometrial cancer in premenopausal women. Elevated adiposity normally provokes aromatase activity in postmenopausal women, leading to enhanced bioavailable oestrogen levels, endometrial cell propagation and stimulated production of IGF1 in endometrial tissue. After menopause (absence of exogenous oestrogen production), when ovarian progesterone synthesis has ceased completely, the more central risk factor appears to be obesity-related endometrial cancer development [28]. Adipocyte normally synthesizes aromatase along with 17β-HSD. In obese persons, there is elevated transformation of the androgens Δ4-Δ4A and T into the estrogens, E1 and E2, respectively, by an enzyme, aromatase. 17β-HSD catalyzes the conversion of Δ4A and E1 into T and E2 respectively. The circulating levels of sex-hormone-binding globulin helps elevate the amounts of E2 and T that can readily diffuse across to target cells through binding with estrogen and androgen receptors. Ultimately, they inhibit apoptosis and promote cellular proliferation in the breast epithelium and endometrium [29]. Obesity leads to hyperinsulinemia and diabetes, which in turn to produce AGE causing a pro-inflammatory state by NF-χB, protein kinase, and intracellular adhesion molecules. Based on the reduction of NO and more leucocyte infiltration in the vessels this causes endothelial and microvascular dysfunction, which are influenced by oxidative stress (ROS), eventually causing atherosclerosis and hypertension [30,32]. In addition, obesity elevates excess glucose and fatty acid oxidation levels that lead to lipid peroxidation and ROS generation, which facilitate lipoprotein toxicity and enhances the rate of hypertension and formation of plaque in blood vessels [27,28,29,30].

4.3. Dyslipidemia and Cardiac Alterations

Obesity is the most widespread cause of dyslipidemia, which produces metabolic syndrome [34]. Overproduction of lipids due to obesity and insulin resistance results in elevated TG storage in non-adipose tissues [35]. In addition, LDL rich in TG, partly degraded by a lipolytic enzyme (hepatic lipase), are transformed into smaller LDL, causing atherosclerosis [36]. Moreover, obesity enhances the threat of angina, cardiac arrest and death, and an unusual heartbeat. Elevated heartbeat in obese individuals increases the frequency of ventricular dysrhythmias and cardiac arrhythmias. The annual rate of cardiac deaths is almost 40 times higher in obese individuals than in non-obese persons [31].

4.4. Metabolic Syndrome

Obesity is the key danger factor for type 2 diabetes. In developed countries, obese individuals are ten times more likely to be identified with diabetes than persons of a healthy weight. At present, about 90% of individuals with diabetes are overweight or obese. Individuals with severe obesity are at greater risk of type 2 diabetes than an obese person with a lower BMI [34]. Rizvi [37] confirmed that the connection between obesity and diabetes, and impaired glucose intolerance. Generally, in obese persons, there is massive adipose tissue, which produces a huge quantity of glycerol, free fatty acids, pro-inflammatory cytokines, advanced glycation end products, intracellular adhesion molecules, and hormones [37]. These substances are highly connected with insulin resistance, which develops hyperinsulinemia with excess pancreatic islet stimuli and decreases or impairment of receptors leading to type 2 diabetes. Ganesan and Gani [38] stated that obesity is the most important component of the metabolic syndrome/disorder, described by the co-occurrence of impaired glucose tolerance, diabetes, insulin resistance, abdominal obesity, hypertension, and the combination of increase TG and decrease HDL cholesterol (Figure 2).

4.5. Cancer and Neurodegenerative Disorders

The World Cancer Research Fund and International Agency for Research on Cancer have suggested that overweight or obese individuals are highly susceptible to get various cancers, namely adenocarcinoma of the esophagus, colon, breast, endometrium, and kidney [39]. Epidemiological studies have also indicated that malignancies of the liver, gallbladder, and pancreas are obesity-associated and that obesity could enhance the danger for other malignancies including thyroid, prostate, leukemia, non-Hodgkin’s lymphoma, multiple myeloma, and melanoma [40]. It has been appraised that about 20% of all cancer demises in the United States can be recognized as connected with overweight and obesity [41,42]. The levels of circulating estrogens are strongly associated with adiposity. These obesity-related malignancies are mostly ascribed to the elevated levels of estrogen in the adipose tissue, inflammation, and infiltration of macrophages [43]. Overweight and obesity cause a mental and emotional state in a person that reduces self-worth to mental depression. Certainly, the incidence rates of anxiety and depression are 3–4 fold increased among obese people [44]. Obesity escalates considerably the menace of neurodegenerative disorders such as Alzheimer’s, multiple sclerosis, Parkinsonism, and amyotrophic lateral sclerosis. For incidence, a solid correlation occurs among BMI and increase concentrations of amyloid. This protein normally accumulates in the Alzheimer’s patient brain, eventually destroying nerve cells and creating mental and social problems [45].

4.6. Sex Hormone Imbalance

Obesity can influence reproductive functions causing problems such as hormonal imbalance, impairment in ovulation, and infertility in malea and females [43]. Obesity has typically been linked with impaired fecundity. Obese women are less likely to conceive per cycle. These women normally suffer distresses to the hypothalamic-pituitary axis, menses disruption and are 3–4 times more likely to get oligo-/anovulation [46]. Decreased levels of estrogen after menopause have also been linked with excess adiposity and accumulation of visceral fat [47]. Besides that, obesity induced by hormonal imbalances is connected to a range of adverse health complications as a result of cardiovascular abnormalities and insulin resistance [46]. It is well known that testosterone is a primary hormone in the pathophysiology of overweight and obesity. Decreased levels of testosterone are connected with high-fat mass, particularly central adiposity and decreased thin mass in males. These characteristic features are connected to metabolic syndrome and testosterone deficiency and are linked with energy inequity, hyperglycemia, insulin resistance and dyslipidemia [48]. Testis dysplasia and alteration of sex hormone levels exist in obese male adolescents. Obesity and accumulation of fat lead to elevated estradiol and declined total and free testosterone that leads to erectile dysfunction [49].

5. Treatment of Obesity

Lifestyle (diet, exercise/physical exercise), pharmacotherapy (weight loss drugs and hormone treatment), and behavioral therapy may cause modest weight reductions in severely obese individuals. Lifestyle with pharmacotherapy has been shown to induce a 2–10% weight loss in obese individuals per annum [50]. However, long-term treatment for obesity is medically a most challenging task.

5.1. Dietary Intervention and Diet Control

There is a great positive link between the quantity of total body fat and visceral adiposity. Hence, any dietary intervention that will diminish total adiposity is likely to induce some loss of abdominal fat. Lifestyle changes also promote weight loss, which can lead to reduced visceral and subcutaneous adipose tissue. The nutritional recommendation with an emphasis on a low-calorie and low-fat diet, with consumption of 800 to 1500 kcal of energy/day, persists. Reduced intake of calories (in the range of 500–1000 kcal) is likely to reduce excess body weight [26]. Their will permit approximately 1 to 2 pounds of weight reduction in a week. Fasting or starvation are also indicated as causes of weight loss in obesity [50]. Nutrition awareness is important for body weight management.

5.2. Physical Activity and Pharmacotherapy

Energy balance comprises the balance between intake of calories and the use of energy [51]. The main causes of obesity are due to the intake of easy and cheap readily available high-calorie fat diets combined with an inactive lifestyle. Hence, negative energy balance (eating less food and enhanced energy expenditure) is the only way to reduce obesity and overweight. Consistent physical activity is a key element to dropping weight. A diversity of physical exercises are helpful and easy to execute. Exercises not only help to reduce weight but also enhance cardio-respiratory fitness and prevent CVD [51]. Exercise is the most effective therapy for obesity together with a low calorie regime. Medication and weight loss surgery can help to reduce weight in obese persons. Medications regularly require long administration periods as many individuals regain their lost weight when medication is suspended. The suspension of medication use by individuals is typically due to their major side effects, cost, and a potential lack of insurance coverage [52].

5.3. Surgical Treatment

Weight loss surgery (WLS)/metabolic surgery is an effective treatment for obesity [53]. The National Institute of Health consensus has recommended surgery only for those obese individuals with high BMI (>35) and who have a serious clinical illness with sleep apnea.

5.4. Natural Products

Natural products that are possible medications for obesity are under investigation. According to Ayurvedic medicine, this can be an outstanding, effective, and safe strategy [54]. Various natural bioactive compounds can influence weight loss and avert diet-induced obesity. Hence, these products have been extensively consumed for the treatment of abdominal obesity and overweight [55,56,57]. Various studies have shown the role of natural metabolites obtained from medicinal plants, which are used in the prevention of obesity and obesity-related chronic disorders. This anti-obesity or weight loss mechanism may be influenced by the medicinal plants, which modulate appetite suppression or the restraint of lipid and carbohydrate metabolic enzymes or interfere with adipogenesis [58,59,60]. Recent animal investigations that have also confirmed the role of various phytochemical-based strategies encourages research into the prevention of obesity. These cellular studies support the notion that the consumption of dietary bioactive compounds decreases the proliferation of preadipocytes, reduces the viability and differentiation of adipocytes, promotes lipolysis and fatty acid β-oxidation, and minimizes triglyceride accumulation and inflammation [7,9]. Furthermore, animal studies have strongly indicateed that the regular consumption of dietary bioactive compounds has a significant influence on obesity, as demonstrated by the reduction of body weight and stored fat mass via increasing energy and fat burning, and regulating glucose hemostasis [61].

5.5. Mushrooms

Mushrooms have been extensively used as foods, nutraceuticals, and medicines since time immemorial [61]. They are recognized as one of the most important food supplements for their vital roles in human health, nutrition, and various illnesses. They contain various bioactive compounds, including primary metabolites that could avert oxidative stress [62]. Secondary metabolites such as polysaccharides (mainly β-d-glucans), heteroglycans, chitinous substances, peptidoglycans, proteoglycans, lectins, RNA components, lectins, lactones, alkaloids, terpenes, flavonoids, terpenoids, steroids, phenols, glycoproteins, nucleotides, fatty acids, vitamins, proteins, amino acids, antibiotics and minerals that have favorable impacts on the human body and protect it from the diseases [62]. These bioactive compounds are excellent antioxidants and anti-inflammatory agents beneficial to the CNS, heart, kidney, and liver [63]. Furthermore, it has been proven that these bioactive compounds act as chemopreventive agents and protect most serious diseases, including diabetes, obesity, CVD and neurodegenerative diseases [1].
Several mushrooms have been widely consumed in most of the developed and developing countries by different ethnicities, races and cultures and are proved to maintain normal health and prevent or treat dreaded illnesses [62]. Nutritional analyses of mushrooms found that edible mushrooms contain vital nutrients, taste, flavor and physiological functions [64]. They are rich in high quality proteins, polyunsaturated fatty acids (with a relatively low content of total fat), vitamins, minerals, and fiber. Mushrooms produce low energy which is favorable for weight loss; the contain low glucose, and high mannitol, that is exactly appropriate for diabetics; and have no cholesterol and low sodium, which is good for people suffering from hypertension [63,64]. Furthermore, mushrooms have a high content of vitamin D and B-complex with a high content of minerals and a significant quantity of many trace elements, especially of selenium, which is a potent antioxidant [65]. In addition to their nutritive value, edible mushrooms have exclusive features in terms of color, palate, flavor, odor, and texture that make them more attractive for human ingestion. Several studies have recommended regular ingestion of certain mushrooms are either as a regular food or as extracted compound (nutraceuticals). Some of these compounds (polysaccharides) are active in both preventing and treating various diseases [64].
Dietary and medicinal mushrooms are widely recognized for their immunomodulatory, hepatoprotective, antiviral, antinociceptive, antitumor, anticancer, antidiabetic, and antimicrobial properties [66,67]. Mushrooms constitute 22,000 well-known species, extensively present on Earth and about 10% of them have been investigated [27]. The dietary mushrooms that have unique functional and medicinal features include Lentinus, Auricularia, Hericium, Grifola, Flammulina, Pleurotus, and Tremella species. Medicinal mushrooms recognized for their medicinal properties include Ganoderma, Trametes, etc. [65]. The beneficial effects of edible mushrooms and their polysaccharides on the gut microbiota [68,69] that is highly associated with obesity and diabetes is presently a dynamic niche research area [70]. A study in mice showed that the extracts of G. lucidum decrease overweight by modulating the microbiota, and hence mushrooms could be a novel prebiotic to control obesity [68]. The impact of a high-fat diet (HFD) on the microbiota in the gut is more complex than the impact on energy equilibrium. Studies showed that HFD-induced alterations in gut microbiota provide a reduction of Bacteroides and Firmicute elevation, which are linked to high energy harvest, fat storage and eventually gut inflammation and permeability [70]. Mushrooms help to regulate dysbiosis and augment antiobesity effects. Holmes [71], and Chang et al. [69] indicated that G. lucidum decreases obesity in mice by regulating the composition of the microbiota. These considerations further suggest that the likely functions of microbiota in the polysaccharide-induced reduction of obesity and diabetes. Furthermore, modulating microbiota with the consumption of mushroom could also help maintain glucose homeostasis and reduce insulin resistance linked to diabetes and obesity. Huang et al. [72] demonstrated that the polysaccharides obtained from Pleurotus tuber-regium mushrooms showed antihyperglycemic and antihyperlipidemic potential and reduced oxidative stress in obese diabetic rats.

6. Anti-Obesity Effects of Edible and Medicinal Mushrooms

Mushrooms have high nutritious value with numerous bioactive compounds that have well-known impacts on various cardiac markers [73,74,75,76,77,78,79,80,81,82]. Mushrooms have been well documented in traditional medicine as having hypocholesterolemic effects. These effects are connected to CVD related lipid metabolism, anti-inflammatory properties, and the prevention of oxidative stress with platelet agglutination [74]. Furthermore, the consumption of mushrooms diminishes CVD and obesity due to their significant amounts of bioactive compounds [8]. Studies further showed that the cholesterol-lowering effect might be due to a decrease in VLDL [73] and decrease in the catalytic functions of HMG-CoA reductase and amplification of the rate of cholesterol catabolism [75]. A study evidenced that mushrooms reduced TG, TC, plasma glucose and hypertension in diabetic rats [73]. These results further suggested that the intake of mushrooms provides health aids by acting on the atherogenic profile under hyper- and normocholesterolemic circumstances in rats [73].
Obesity unfavorably affects systemic immunity via the inflammatory index, and platelet markers [76]. Numerous investigations have examined the anti-obesity effect of polysaccharides obtained from different mushrooms in vitro as well as in vivo. Polysaccharide obtained from Coriolus versicolor triggered mice splenocytes via the MAPK-NF-κB signaling pathway that induces an immunomodulatory effect [77]. A polysaccharide obtained from Tremella fuciformis prevented the variation of 3T3-L1 adipocytes by decreasing the expression of mRNA suggesting the possible significance of the polysaccharide as an anti-obesity prebiotic [63]. Treatment of adipocytes with G. lucidum reduced adipogenic transcription factor expression that stimulates transportation, storage of glucose and lipids, and activates AMPK signaling pathways suggesting the potential significance of the polysaccharide as an antiobesity and antidiabetic agent [78]. Long-term (1 year) and short-term (4-day) clinical studies with obese or diabetic participants asked them to evaluate the impact of substituting 20% of high-energy beef with 20% of low-energy white button mushrooms in the diet [79,80]. The results showed that the mushroom regime consumers had lesser BMI, decreased belly circumference, and increase satiety without diminishing palatability. The authors of the studies concluded that the consumption of white button mushrooms (Agaricus bisporus) has potential as an antidiabetic and antiobesity. Similarly this work has been extended to include other extremely health-promoting mushroom varieties, like Hericium erinaceus (Lion’s mane) and Lentinus edodes (shiitake) species [81,82]. The in vitro and in vivo actions of edible and medicinal mushrooms and its anti-obesity potentials are summarized in Table 1.

6.1. Actions on Hypertension

Hypertension is regulated by several mechanisms, one of the most significant of which is a renin-angiotensin-aldosterone system (RAS). Normally RAS is regulated by the Zn-metallopeptidase enzyme, angiotensin-converting enzyme (ACE). The main function of ACE is involvement in the transformation of an Ang-I decapeptide into an Ang-II octapeptide. Typically Ang-II (a potent vasoconstrictor), cooperates with the Ang-II type 1 receptor (AT1) provoking the synthesis of aldosterone, which elevates sodium and water retention in the kidney and correspondingly raises blood pressure by enhancing the volume of the intravascular fluid [83].
ACE inhibitors are used as an effective prescription for the inhibition and treatment of hypertension-related diseases [29]. Commercially available ACE inhibitors are chemically synthesized and clinically used as antihypertensive drugs [84]. The usage of these synthetic ACE inhibitors has side effects such as a cough, dysgeusia and various hypersensitivity reactions. Therefore, it would be useful to develop and use safe and comparatively low-cost ACE inhibitors of natural origin (Figure 3). ACE inhibitors have been reported to diminish mortality in patients with hypertension [85]. Recently, investigators have described that Pleurotus ostreatus [86], P. cystidiosus [85], P. cornucopiae [87], Auricularia auricula-judae [88], Ganoderma leucocontextum [65], Grifola frondosa [89], Agaricus bisporus [30] and Leucopaxillus tricolor [29] are all ACE inhibitors that decrease hypertension. Wild mushrooms in Nepal that also have ACE inhibitor activities were tested by Bang et al. [90].

6.2. Actions on Dyslipidemia

Edible mushrooms are rich in dietary fiber, vitamins, proteins, microelements, and low in fat that, making them the ultimate diet for treating atherosclerotic plaque [88]. Mushrooms prevented weight gain in a rodent study suggesting a precious treatment for obesity and greater significance in the prevention of hyperlipidemia and CVD [1]. Pleurotus ostreatus is an edible mushroom, which decreases TC, TG, blood glucose and BP in diabetic individuals. These outcomes suggested that ingestion of P. ostreatus offers greater health benefits by acting on the atherogenic lipid system [75]. Edible white button mushroom (Agaricus blazei), Kluyveromyces marxianus [91], P. ostreatus [92] and Auricularia polytricha [93] are found to be well-known lipid-lowering agents by competitively preventing HMG-CoA reductase activity, which plays a vital role in cholesterol biosynthesis [35]. The results of P. ostreatus on serum TG levels could be enlightened due to increased lipoprotein lipase activity by increasing lipase mRNA expression [75] and suppression of diacylglycerol acyl-transferase, which catalyzes the final step in TG biosynthesis in rat liver microsomes [74]. The mechanisms associated with cholesterol biosynthesis implicated in the hypocholesterolemic impact of mushrooms are represented in Figure 4. An adequate level of PUFAs is found in edible mushrooms, which facilitates the reduction of serum cholesterol [91]. As they lacking the trans-isomers of unsaturated fatty acids, mushrooms can elevate the serum TC to HDL that reduces the cardiovascular menace [74]. Intake of dietary fiber may also affect serum lipid levels, decrease TC, LDL concentrations and eventually reduce CVD [65]. Mushrooms contain glucan-like viscous gels that prevent the TC and TG absorption. These sticky consistencies are highly associated with augmentation of fecal bile acids and SCFA excretion, which prevents acetate integration (a precursor of sterols and synthesis of fatty acids) to become serum lipids. Auricularia auricula and Tremella fuciformis possess high fiber content, which produces a lowering of LDL cholesterol levels and prevents CVD [88]. These findings might be the result of prevention of TG synthesis by enhancing the SCFA production through the dietary fiber fermentation by gut microbiota [72].

7. Conclusions and Future Perspectives

Obesity is a dreaded disease that affects a great proportion of the global population and contributes to extensive morbidity and death. Weight management is a lifelong progression as enduring weight decline is very hard to attain. The main cause of obesity is a disproportion between calorie intake and energy outlay resulting from multifaceted relations between hereditary and environmental influences. Effective weight control programs are urgently required to stabilize calorie intake with energy expenditure. Diet and physical activity can usually regulate weight control. Mushrooms are highly nutritive species containing enormous amounts of bioactive compounds (polysaccharides, fibers, terpenes, polyphenols, sterols, flavonoids, and alkaloids) that are potentially antioxidant-rich constituents with effects on numerous cardiac biomarkers to treat obesity-related cardiovascular system illnesses. Various animal studies have demonstrated that regular consumption of mushrooms significantly reduces hypertension, atherosclerosis, dyslipidemia, inflammation, and obesity. Nevertheless, this practice ought to be combined with regular physical exercise, as well as dietary and lifestyle alterations. The practice of regular consumption of mushroom might however result in synergistic and improved effects.

Author Contributions

K.G. and B.X. conceived and designed the manuscript. K.G. wrote the review; B.X. critically revised and improved the manuscript.


The work was jointly supported by a grant UIC201714 from Beijing Normal University-Hong Kong Baptist University United International College and one research grant from Zhuhai Higher Education Construction Project (Zhuhai Key Laboratory of Agricultural Product Quality and Food Safety).

Conflicts of Interest

The authors declare no conflict of interest.


17β-HSD17β-hydroxysteroid dehydrogenase
ACC1acetyl-CoA carboxylase 1
ACEangiotensin converting enzyme
ACO1-aminocyclopropane-1-carboxylate oxidase
AGEadvanced glycation end products
AGPAT1-acylglycerol-3-phosphate O-acyltransferase 1
AgRPagouti-related peptide
ALTalanine transaminase
AMPK5′ adenosine monophosphate-activated protein kinase
Ang-Iangiotensin I
Ang-IIangiotensin II
ASTaspartate transaminase
AT-1angiotensin II type 1 receptor
BMIbody mass index
BMRbasal metabolic rate
BUNblood urea nitrogen
CNScentral nervous system
CPT1carnitine Palmitoyltransferase 1A
CRPc-reactive protein
CVDcardiovascular diseases
DGATdiacylglycerol O-Acyltransferase 1
FFAfree fatty acids
GPATRglycerol-3-phosphate acyltransferase
GSH-Pxglutathione peroxidase
HDLhigh density lipoprotein
HFDhigh fat diet
HMG-CoAβ-hydroxy, β methyl glutaryl COA
ICAMIntercellular Adhesion Molecule
IGF1IGF binding protein 1
IL-1interleukin 1
IL-6interleukin 6
LDLlow density lipoprotein
LPOlipid peroxidation
MAPKmitogen-activated protein kinases
MCHmelanin concentrating hormone
mRNAmessenger ribonucleic acids
NF-χBnuclear factor kappa B
NOnitric oxide
NPYneuropeptide Y
OGTToral glucose tolerance test
PPAR-αperoxisome proliferator-activated receptor alpha
PUFApoly unsaturated fatty acids
RASrenin-angiotensin-aldosterone system
ROSreactive oxygen species
SCD1stearoyl-CoA desaturase 1
SCFAshort chain fatty acids
SCFAshort chain fatty acids
SODsuperoxide dismutase
SREBP-1csterol regulatory element-binding transcription factor 1
T-AOCtotal antioxidant capacity
TBARSthiobarbituric acid reactive substances
TCtotal cholesterol
TNF-αtumour necrosis factor-α
UCP2mitochondrial uncoupling proteins 2
UCP3mitochondrial uncoupling proteins 3
VCAMvascular cell adhesion molecule
VLDLvery low density lipoprotein
WHOworld health organization
WLSweight loss surgery


  1. Kanagasabapathy, G.; Malek, S.N.A.; Mahmood, A.A.; Chua, K.H.; Vikineswary, S.; Kuppusamy, U.R. Beta-glucan-rich extract from Pleurotus sajor-caju (Fr.) Singer prevents obesity and oxidative stress in C57BL/6J Mice fed on a high-fat diet. Evid. Based Complement. Altern. Med. 2013, 2013, 185259. [Google Scholar] [CrossRef] [PubMed]
  2. Kim, J.Y.; Tfayli, H.; Michaliszyn, S.F.; Arslanian, S. Impaired lipolysis diminished fat oxidation and metabolic inflexibility in obese girls with polycystic ovary syndrome. J. Clin. Endocrinol. MeTable. 2018, 103, 546–554. [Google Scholar] [CrossRef] [PubMed]
  3. Kim, S.J.; Bang, C.Y.; Guo, Y.R.; Choung, S.Y. Anti-obesity effects of Aster spathulifolius extract in high-fat-diet-induced obese rats. J. Med. Food 2016, 19, 353–364. [Google Scholar] [CrossRef] [PubMed]
  4. Kennett, G.A.; Clifton, P.G. New approaches to the pharmacological treatment of obesity: Can they break through the efficacy barrier? Pharmacol. Biochem. Behav. 2010, 97, 63–83. [Google Scholar] [CrossRef] [PubMed]
  5. Bardou, M.; Barkun, A.N.; Martel, M. Obesity and colorectal cancer. Gut 2013, 62, 933–947. [Google Scholar] [CrossRef] [PubMed]
  6. Kuwabara, W.M.T.; Panveloski-Costa, A.C.; Yokota, C.N.F.; Pereira, J.N.B.; Filho, J.M.; Torres, R.P.; Hirabara, S.M.; Curi, R.; Alba-Loureiro, T.C. Comparison of Goto-Kakizaki rats and high fat diet-induced obese rats: Are they reliable models to study Type 2 Diabetes mellitus? PLoS ONE 2017, 12, e0189622. [Google Scholar] [CrossRef] [PubMed]
  7. Gooda Sahib Jambocus, N.; Saari, N.; Ismail, A.; Khatib, A.; Mahomoodally, M.F.; Abdul Hamid, A. An investigation into the antiobesity effects of Morinda citrifolia L. leaf extract in high-fat diet-induced obese rats using a (1)H NMR metabolomics approach. J. Diabetes Res. 2016, 2016, 2391592. [Google Scholar] [PubMed]
  8. Yamada, T.; Oinuma, T.; Niihashi, M.; Mitsumata, M.; Fujioka, T.; Hasegawa, K.; Nagaoka, H.; Itakura, H. Effects of Lentinus edodes mycelia on dietary-induced atherosclerotic involvement in rabbit aorta. J. Atheroscler. Thromb. 2002, 9, 149–156. [Google Scholar] [CrossRef] [PubMed]
  9. Kasabri, V.; Al-Hallaq, E.K.; Bustanji, Y.K.; Abdul-Razzak, K.K.; Abaza, I.F.; Afifi, F.U. Antiobesity and antihyperglycaemic effects of Adiantum capillus-veneris extracts: In vitro and in vivo evaluations. Pharm. Biol. 2017, 55, 164–172. [Google Scholar] [CrossRef] [PubMed]
  10. World Health Organization. Obesity and Overweight. Fact Sheet. Updated in June 2016. Available online: (accessed on 28 June 2016).
  11. Rodríguez-Rodero, S.; Menéndez-Torre, E.; Fernández-Bayón, G.; Morales-Sánchez, P.; Sanz, L.; Turienzo, E.; González, J.J.; Martinez-Faedo, C.; Suarez-Gutiérrez, L.; Ares, J.; et al. Altered intragenic DNA methylation of HOOK2 gene in adipose tissue from individuals with obesity and type 2 diabetes. PLoS ONE 2017, 12, e0189153. [Google Scholar] [CrossRef] [PubMed]
  12. Flegal, K.M.; Carroll, M.D.; Ogden, C.L.; Curtin, L.R. Prevalence and trends in obesity among United States adults, 1999–2008. J. Am. Med. Assoc. 2010, 303, 235–241. [Google Scholar] [CrossRef] [PubMed]
  13. Gooding, H.C.; Ning, H.; Gillman, M.W.; Shay, C.; Allen, N.; Goff, D.C., Jr.; Lloyd-Jones, D.; Chiuve, S. Application of a lifestyle-based tool to estimate premature cardiovascular disease events in young adults: The coronary artery risk development in young adults (CARDIA) Study. JAMA Int. Med. 2017, 177, 1354–1360. [Google Scholar] [CrossRef] [PubMed]
  14. Elffers, T.W.; de Mutsert, R.; Lamb, H.J.; de Roos, A.; Willems van Dijk, K.; Rosendaal, F.R.; Jukema, J.W.; Trompet, S. Body fat distribution, in particular, visceral fat, is associated with cardiometabolic risk factors in obese women. PLoS ONE 2017, 12, e0185403. [Google Scholar] [CrossRef] [PubMed]
  15. Reales, G.; Rovaris, D.L.; Jacovas, V.C.; Hünemeier, T.; Sandoval, J.R.; Salazar-Granara, A.; Demarchi, D.A.; Tarazona-Santos, E.; Felkl, A.B.; Serafini, M.A.; et al. A tale of agriculturalists and hunter-gatherers: Exploring the thrifty genotype hypothesis in native South Americans. Am. J. Physiol. Anthropol. 2017, 163, 591–601. [Google Scholar] [CrossRef] [PubMed]
  16. Provencher, M.D.; Bélanger, M.È.; Shriqui, C.; Lachance, I.; Bonneville, S. Psychoeducation for overweight patients with psychiatric disorders: The Wellness program developed in Quebec. Encephale 2016, 42, 201–207. [Google Scholar] [CrossRef] [PubMed]
  17. Vandyk, A.D.; Baker, C. Qualitative descriptive study exploring schizophrenia and the everyday effect of medication-induced weight gain. Int. J. Ment. Health Nurs. 2012, 21, 349–357. [Google Scholar] [CrossRef] [PubMed]
  18. Charlotte, M.; Schwartz, E.; Slade, E.; Medoff, D.; Li, L.; Dixon, L.; Kilbourne, A.M.; Kreyenbuhl, J. Gender differences in mood stabilizer medications prescribed to Veterans with serious mental illness. J. Affect. Disord. 2015, 188, 112–117. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Nihalani, N.; Schwartz, T.L.; Siddiqui, U.A.; Megna, J.L. Weight gain, obesity, and psychotropic prescribing. J. Obes. 2011, 2011, 893629. [Google Scholar] [CrossRef] [PubMed]
  20. Wierucka-Rybak, M.; Bojanowska, E. Bacteria, viruses, and hypothalamic inflammation: Potential new players in obesity. Postepy Hig. Med. Dosw. 2014, 68, 271–279. [Google Scholar] [CrossRef]
  21. Karlsson, E.A.; Beck, M.A. The burden of obesity on infectious disease. Exp. Biol. Med. 2010, 235, 1412–1424. [Google Scholar] [CrossRef] [PubMed]
  22. Kirchner, H.; Heppner, K.M.; Holland, J.; Kabra, D.; Tschöp, M.H.; Pfluger, P.T. Ablation of ghrelin O-acyltransferase does not improve glucose intolerance or body adiposity in mice on a leptin-deficient ob/ob background. PLoS ONE 2013, 8, e61822. [Google Scholar] [CrossRef] [PubMed]
  23. Palou, M.; Sanchez, J.; Rodriguez, A.M.; Priego, T.; Pico, C. Induction of NPY/AgRP orexigenic peptide expression in rat hypothalamus is an early event in fasting: Relationship with circulating leptin, insulin, and glucose. Cell Physiol. Biochem. 2009, 23, 115–124. [Google Scholar] [CrossRef] [PubMed]
  24. Yamamoto, J.; Imai, J.; Izumi, T.; Takahashi, H.; Kawana, Y.; Takahashi, K.; Kodama, S.; Kaneko, K.; Gao, J.; Uno, K.; et al. Neuronal signals regulate obesity-induced β-cell proliferation by FoxM1 dependent mechanism. Nat. Commun. 2017, 8, 1930. [Google Scholar] [CrossRef] [PubMed]
  25. Das Graças Coelho de Souza, M.; Kraemer-Aguiar, L.G.; Bouskela, E. Inflammation-induced microvascular dysfunction in obesity—A translational approach. Clin. Hemorheol. Microcirc. 2016, 64, 645–654. [Google Scholar] [CrossRef] [PubMed]
  26. Ganesan, K.; Sukalingam, K.; Xu, B. Impact of consumption and cooking manners of vegetable oils on cardiovascular diseases—A critical review. Trends Food Sci. Technol. 2018, 71, 132–154. [Google Scholar] [CrossRef]
  27. Tsubone, H.; Makimura, Y.; Hanafusa, M.; Yamamoto, Y.; Tsuru, Y.; Motoi, M.; Amano, S. Agaricus brasiliensis KA21 improves circulatory functions in spontaneously hypertensive rats. J. Med. Food 2014, 17, 295–301. [Google Scholar] [CrossRef] [PubMed]
  28. Sukalingam, K.; Ganesan, K. Rhesus blood groups associated with risk to obesity and diabetes mellitus: A report on Punjabi population in Selangor, Malaysia. Int. J. Integr. Med. Sci. 2015, 2, 105–109. [Google Scholar]
  29. Geng, X.; Tian, G.; Zhang, W.; Zhao, Y.; Zhao, L.; Ryu, M.; Wang, H.; Ng, T.B. Isolation of an Angiotensin I-Converting Enzyme inhibitory protein with antihypertensive effect in spontaneously hypertensive rats from the edible wild mushroom Leucopaxillus tricolor. Molecules 2015, 20, 10141–10153. [Google Scholar] [CrossRef] [PubMed]
  30. Lau, C.C.; Abdullah, N.; Shuib, A.S.; Aminudin, N. Novel angiotensin I-converting enzyme inhibitory peptides derived from edible mushroom Agaricus bisporus (J.E. Lange) Imbach identified by LC-MS/MS. Food Chem. 2014, 148, 396–401. [Google Scholar] [CrossRef] [PubMed]
  31. Sowers, J.R. Diabetes mellitus and vascular disease. Hypertension 2013, 61, 943–947. [Google Scholar] [CrossRef] [PubMed]
  32. Fukushima, M.; Nakano, M.; Morii, Y.; Ohashi, T.; Fujiwara, Y.; Sonoyama, K. Hepatic LDL receptor mRNA in rats is increased by dietary mushroom (Agaricus bisporus) fiber and sugar beet fiber. J. Nutr. 2000, 130, 2151–2156. [Google Scholar] [CrossRef] [PubMed]
  33. Kurukulasuriya, L.R.; Stas, S.; Lastra, G.; Manrique, C.; Sowers, J.R. Hypertension in obesity. Med. Clin. N. Am. 2011, 95, 903–917. [Google Scholar] [CrossRef] [PubMed]
  34. Ece, I.; Yilmaz, H.; Alptekin, H.; Yormaz, S.; Colak, B.; Yilmaz, F.; Sahin, M. Comparative effectiveness of laparoscopic sleeve gastrectomy on morbidly obese, super-obese, and super-super obese patients for the treatment of morbid obesity. Obes. Surg. 2017, 28, 1484–1491. [Google Scholar] [CrossRef] [PubMed]
  35. Jeong, S.C.; Jeong, Y.T.; Yang, B.K.; Islam, R.; Koyyalamudi, S.R.; Pang, G.; Cho, K.Y.; Song, C.H. White button mushroom (Agaricus bisporus) lowers blood glucose and cholesterol levels in diabetic and hypercholesterolemic rats. Nutr. Res. 2010, 30, 49–56. [Google Scholar] [CrossRef] [PubMed]
  36. Ganesan, K.; Gani, S.B. Attenuation of curcumin on isoproterenol-induced alterations in cardiac marker enzymes in Wistar albino rats. Int. J. Appl. Biosci. 2014, 2, 78–83. [Google Scholar]
  37. Rizvi, A.A. Addressing hypertension in the patient with type 2 diabetes mellitus: Pathogenesis, goals, and therapeutic approach. Eur. Med. J. Diabetes 2017, 5, 84–92. [Google Scholar] [PubMed]
  38. Ganesan, K.; Gani, S.B. Relationship between ABO, Rh Blood Groups, and Diabetes Mellitus, obesity in Namakkal town, Tamilnadu. Int. J. Adv. Pharm. Biol. Chem. 2014, 3, 995–998. [Google Scholar]
  39. De Pergola, G.; Silvestris, F. Obesity as a major risk factor for cancer. J. Obes. 2013, 2013, 291546. [Google Scholar] [CrossRef] [PubMed]
  40. Allott, E.H.; Masko, E.M.; Freedland, S.J. Obesity and prostate cancer: Weighing the evidence. Eur. Urol. 2013, 63, 800–809. [Google Scholar] [CrossRef] [PubMed]
  41. Ganesan, K.; Sukalingam, K.; Xu, B. Impact of consumption of repeatedly heated cooking oils on the incidence of various cancers—A critical review. Crit. Rev. Food Sci. Nutr. 2017, 58, 1–18. [Google Scholar] [CrossRef] [PubMed]
  42. Ganesan, K.; Xu, B. Molecular targets of vitexin and isovitexin in cancer therapy: A critical review. Ann. N.Y. Acad. Sci. 2017, 1401, 102–113. [Google Scholar] [CrossRef] [PubMed]
  43. Bao, B.; Wang, Z.; Li, Y.; Kong, D.; Ali, S. The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochim. Biophys. Acta 2011, 1815, 135–146. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Xu, Q.; Anderson, D.; Lurie-Beck, J. The relationship between abdominal obesity and depression in the general population: A systematic review and meta-analysis. Obes. Res. Clin. Pract. 2011, 5, e267–e278. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Hagan, K.A.; Munger, K.L.; Ascherio, A.; Grodstein, F. Epidemiology of Major Neurodegenerative Diseases in Women: Contribution of the Nurses’ Health Study. Am. J. Public Health 2016, 26, 1650–1655. [Google Scholar] [CrossRef] [PubMed]
  46. Brewer, C.J.; Balen, A.H. The adverse effects of obesity on conception and implantation. Reproduction 2010, 140, 347–364. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Tchernof, A.; Després, J.-P. Pathophysiology of Human Visceral Obesity: An Update. Physiol. Rev. 2013, 93, 359–404. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Kelly, D.M.; Jones, T.H. Testosterone and obesity. Obes. Rev. 2015, 16, 581–606. [Google Scholar] [CrossRef] [PubMed]
  49. Zhang, L.D.; Li, H.C.; Gao, M.; Wang, L.; Deng, Q.; Shi, T.; He, J.L.; Chong, T.; Wang, Z.M. Sexual development characteristics and sex hormone levels in obese male adolescents. Zhonghua Nan Ke Xue 2013, 19, 434–438. [Google Scholar] [PubMed]
  50. Steenackers, N.; Gesquiere, I.; Matthys, C. The relevance of dietary protein after bariatric surgery: What do we know? Curr. Opin. Clin. Nutr. Metab. Care 2018, 21, 58–63. [Google Scholar] [CrossRef] [PubMed]
  51. Frith, E.; Loprinzi, P.D. The protective effects of a novel fitness-fatness index on all-cause mortality among adults with cardiovascular disease. Clin. Cardiol. 2017, 40, 469–473. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Gontarev, S.; Kalac, R.; Zivkovic, V.; Velickovska, L.A.; Telai, B. The association between high blood pressure, physical fitness and fatness in adolescents. Nutr. Hosp. 2017, 34, 35–40. [Google Scholar] [CrossRef] [PubMed]
  53. Kissane, N.A.; Pratt, J.S.A. Medical and surgical treatment of obesity. Best Pract. Res. Clin. Anaesthesiol. 2011, 25, 11–25. [Google Scholar] [CrossRef] [PubMed]
  54. Bessesen, D.H.; Van Gaal, L.F. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol. 2018, 6, 237–248. [Google Scholar] [CrossRef]
  55. Banu, G.S.; Kumar, G.; Pandian, M.R. Cholesterol lowering activity of the aqueous fruit extract of Trichosanthes dioica Roxb. in normal and streptozotocin diabetic rats. J. Clin. Diagn. Res. 2007, 1, 561–569. [Google Scholar]
  56. Kumar, G.; Murugesan, A.G. Hypolipidaemic activity of Helicteres isora L. bark extracts in streptozotocin induced diabetic rats. J. Ethnopharmacol. 2008, 116, 161–166. [Google Scholar] [CrossRef] [PubMed]
  57. Ganesan, K.; Ramasamy, M.; Gani, S.B. Antihyperlipideamic effect of Solanum trilobatum L. leaves extract on streptozotocin induced diabetic rats. Asian J. Biomed. Pharm. Sci. 2013, 3, 51–56. [Google Scholar]
  58. Kumar, G.; Banu, G.S.; Murugesan, A.G. Attenuation of Helicteres isora L. bark extracts on streptozotocin-induced alterations in glycogen and carbohydrate metabolism in albino rats. Hum. Exp. Toxicol. 2009, 28, 689–696. [Google Scholar] [CrossRef] [PubMed]
  59. Kumar, G.; Banu, G.S.; Murugesan, A.G. Effect of Helicteres isora bark extracts on heart antioxidant status and lipid peroxidation in streptozotocin diabetic rats. J. Appl. Biomed. 2008, 6, 89–95. [Google Scholar]
  60. Jayachandran, M.; Zhang, T.; Ganesan, K.; Xu, B.; Chung, S.S.M. Isoquercetin ameliorates hyperglycemia and regulates key enzymes of glucose metabolism via insulin signaling pathway in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 2018, 829, 112–120. [Google Scholar] [CrossRef] [PubMed]
  61. Friedman, M. Mushroom polysaccharides: Chemistry and antiobesity, antidiabetes, anticancer, and antibiotic properties in cells, rodents, and humans. Foods 2016, 5, 80. [Google Scholar] [CrossRef] [PubMed]
  62. Chang, S.T.; Wasser, S.P. The Role of Culinary-Medicinal Mushrooms on Human Welfare with a Pyramid Model for Human Heath. Int. J. Med. Mushrooms 2012, 14, 95–134. [Google Scholar] [CrossRef] [PubMed]
  63. Jeong, H.J.; Yoon, S.J.; Pyun, Y.R. Polysaccharides from edible mushroom Hinmogi (Tremella fuciformis) inhibit differentiation of 3T3-L1 adipocytes by reducing mRNA expression of PPARγ, C/EBPα, and leptin. Food Sci. Biotechnol. 2008, 17, 267–273. [Google Scholar]
  64. Nyam, K.L.; Chow, C.F.; Tan, C.S.; Ng, S.T. Antidiabetic Properties of the Tiger’s milk medicinal mushroom, Lignosus rhinocerotis (Agaricomycetes), in streptozotocin-induced diabetic rats. Int. J. Med. Mushrooms 2017, 19, 607–617. [Google Scholar] [CrossRef] [PubMed]
  65. Wang, K.; Bao, L.; Xiong, W.; Ma, K.; Han, J.; Wang, W.; Yin, W.; Liu, H. Lanostane triterpenes from the tibetan medicinal mushroom Ganoderma leucocontextum and their inhibitory effects on HMG-CoA reductase and α-glucosidase. J. Nat. Prod. 2015, 78, 1977–1989. [Google Scholar] [CrossRef] [PubMed]
  66. Zhang, J.J.; Li, Y.; Zhou, T.; Xu, D.P.; Zhang, P.; Li, S.; Li, H.B. Bioactivities and health benefits of mushrooms mainly from China. Molecules 2016, 21, 938. [Google Scholar] [CrossRef] [PubMed]
  67. Ng, T.B.; Cheung, R.C.; Wong, J.H.; Chan, Y.S.; Dan, X.; Pan, W.; Wang, H.; Guan, S.; Chan, K.; Ye, X.; et al. Fungal proteinaceous compounds with multiple biological activities. Appl. Microbiol. Biotechnol. 2016, 100, 6601–6617. [Google Scholar] [CrossRef] [PubMed]
  68. Delzenne, N.M.; Bindels, L.B. Gut microbiota: Ganoderma lucidum, a new prebiotic agent to treat obesity? Nat. Rev. Gastroenterol. Hepatol. 2015, 12, 553–554. [Google Scholar] [CrossRef] [PubMed]
  69. Chang, C.J.; Lin, C.S.; Lu, C.C.; Martel, J.; Ko, Y.F.; Ojcius, D.M.; Tseng, S.F.; Wu, T.R.; Chen, Y.Y.; Young, J.D.; et al. Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota. Nat. Commun. 2015, 6, 7489. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  70. Murphy, E.A.; Velazquez, K.T.; Herbert, K.M. Influence of high-fat diet on gut microbiota: A driving force for chronic disease risk. Curr. Opin. Clin. Nutr. Metab. Care 2015, 18, 515–520. [Google Scholar] [CrossRef] [PubMed]
  71. Holmes, D. Obesity: Medicinal mushroom reduces obesity by modulating microbiota. Nat. Rev. Endocrinol. 2015, 11, 504. [Google Scholar] [CrossRef] [PubMed]
  72. Huang, H.Y.; Korivi, M.; Yang, H.T.; Huang, C.C.; Chaing, Y.Y.; Tsai, Y.C. Effect of Pleurotus tuber-regium polysaccharides supplementation on the progression of diabetes complications in obese-diabetic rats. Chin. J. Physiol. 2014, 57, 198–208. [Google Scholar] [CrossRef] [PubMed]
  73. Wang, L.; Xu, N.; Zhang, J.; Zhao, H.; Lin, L.; Jia, S.; Jia, L. Antihyperlipidemic and hepatoprotective activities of residue polysaccharide from Cordyceps militaris SU-12. Carbohydr. Polym. 2015, 131, 355–362. [Google Scholar] [CrossRef] [PubMed]
  74. Sun, Q.; Ma, J.; Campos, H.; Hankinson, S.E.; Manson, J.E.; Stampfer, M.J.; Rexrode, K.M.; Willett, W.C.; Hu, F.B. A prospective study of trans fatty acids in erythrocytes and risk of coronary heart disease. Circulation 2007, 115, 1858–1865. [Google Scholar] [CrossRef] [PubMed]
  75. Bobek, P.; Hromadová, M.; Ozdín, L. Oyster mushroom (Pleurotus ostreatus) reduces the activity of 3-hydroxy-3-methylglutaryl CoA reductase in rat liver microsomes. Experientia 1995, 51, 589–591. [Google Scholar] [CrossRef] [PubMed]
  76. Furuncuoğlu, Y.; Tulgar, S.; Dogan, A.N.; Cakar, S.; Tulgar, Y.K.; Cakiroglu, B. How obesity affects the neutrophil/lymphocyte and platelet/lymphocyte ratio, systemic immune-inflammatory index and platelet indices: A retrospective study. Eur. Rev. Med. Pharmacol. Sci. 2016, 20, 1300–1306. [Google Scholar] [PubMed]
  77. Mao, G.H.; Ren, Y.; Feng, W.W.; Li, Q.; Wu, H.Y.; Jin, D.; Zhao, T.; Xu, C.Q.; Yang, L.Q.; Wu, X.Y. Antitumor and immunomodulatory activity of a water-soluble polysaccharide from Grifola frondosa. Carbohydr. Polym. 2015, 134, 406–412. [Google Scholar] [CrossRef] [PubMed]
  78. Thyagarajan-Sahu, A.; Lane, B.; Sliva, D. ReishiMax, mushroom-based dietary supplement, inhibits adipocyte differentiation, stimulates glucose uptake and activates AMPK. BMC Complement. Altern. Med. 2011, 11, 74. [Google Scholar] [CrossRef] [PubMed]
  79. Cheskin, L.J.; Davis, L.M.; Lipsky, L.M.; Mitola, A.H.; Lycan, T.; Mitchell, V.; Mickle, B.; Adkins, E. Lack of energy compensation over 4 days when white button mushrooms are substituted for beef. Appetite 2008, 51, 50–57. [Google Scholar] [CrossRef] [PubMed]
  80. Poddar, K.H.; Ames, M.; Hsin-Jen, C.; Feeney, M.J.; Wang, Y.; Cheskin, L.J. Positive effect of mushrooms substituted for meat on body weight, body composition, and health parameters. A 1-year randomized clinical trial. Appetite 2013, 71, 379–387. [Google Scholar] [CrossRef] [PubMed]
  81. Kim, S.P.; Park, S.O.; Lee, S.J.; Nam, S.H.; Friedman, M. A polysaccharide isolated from the liquid culture of Lentinus edodes (Shiitake) mushroom mycelia containing black rice bran protects mice against a Salmonella lipopolysaccharide-induced endotoxemia. J. Agric. Food Chem. 2013, 61, 10987–10994. [Google Scholar] [CrossRef] [PubMed]
  82. Friedman, M. Chemistry, Nutrition, and Health-Promoting Properties of Hericium erinaceus (Lion’s Mane) Mushroom Fruiting Bodies and Mycelia and Their Bioactive Compounds. J. Agric. Food Chem. 2015, 63, 7108–7123. [Google Scholar] [CrossRef] [PubMed]
  83. Lafarga, T.; Hayes, M. Bioactive peptides from meat muscle and by-products: Generation, functionality, and application as functional ingredients. Meat Sci. 2014, 98, 227–239. [Google Scholar] [CrossRef] [PubMed]
  84. Kang, M.G.; Kim, Y.H.; Bolormaa, Z.; Kim, M.K.; Seo, G.S.; Lee, J.S. Characterization of an antihypertensive angiotensin I-converting enzyme inhibitory peptide from the edible mushroom Hypsizygus marmoreus. BioMed Res. Int. 2013, 2013, 283964. [Google Scholar] [CrossRef] [PubMed]
  85. Lau, C.C.; Abdullah, N.; Shuib, A.S. Novel angiotensin I-converting enzyme inhibitory peptides derived from an edible mushroom, Pleurotus cystidiosus O.K. Miller identified by LC-MS/MS. BMC Complement. Altern. Med. 2013, 13, 313. [Google Scholar] [CrossRef] [PubMed]
  86. Alam, N.; Yoon, K.N.; Lee, T.S.; Lee, U.Y. Hypolipidemic activities of dietary Pleurotus ostreatus in hypercholesterolemic rats. Mycobiology 2011, 39, 45–51. [Google Scholar] [CrossRef] [PubMed]
  87. Jang, J.H.; Jeong, S.C.; Kim, J.H.; Lee, Y.H.; Ju, Y.C.; Lee, J.S. Characterization of a new antihypertensive angiotensin I-converting enzyme inhibitory peptide from Pleurotus cornucopiae. Food Chem. 2011, 127, 412–418. [Google Scholar] [CrossRef] [PubMed]
  88. Reza, M.A.; Hossain, M.A.; Damte, D.; Jo, W.S.; Hsu, W.H.; Park, S.C. Hypolipidemic and hepatic steatosis preventing activities of the wood ear medicinal mushroom Auricularia auricula-judae (Higher Basidiomycetes) ethanol extract in vivo and in vitro. Int. J. Med. Mushrooms 2015, 17, 723–734. [Google Scholar] [CrossRef] [PubMed]
  89. Fukushima, M.; Ohashi, T.; Fujiwara, Y.; Sonoyama, K.; Nakano, M. Cholesterol-lowering effects of maitake (Grifola frondosa) fiber, shiitake (Lentinus edodes) fiber, and enokitake (Flammulina velutipes) fiber in rats. Exp. Biol. Med. 2001, 226, 758–765. [Google Scholar] [CrossRef]
  90. Bang, T.H.; Suhara, H.; Doi, K.; Ishikawa, H.; Fukami, K.; Parajuli, G.P.; Katakura, Y.; Yamashita, S.; Watanabe, K.; Adhikari, M.K. Wild mushrooms in Nepal: Some potential candidates as antioxidant and ACE-inhibition sources. J. Evid. Based Complement. Altern. Med. 2014, 2014, 195305. [Google Scholar]
  91. Xie, Y.; Zhang, H.; Liu, H.; Xiong, L.; Gao, X.; Jia, H.; Lian, Z.; Tong, N.; Han, T. Hypocholesterolemic effects of Kluyveromyces marxianus M3 isolated from Tibetan mushrooms on diet-induced hypercholesterolemia in rat. Braz. J. Microbiol. 2015, 46, 389–395. [Google Scholar] [CrossRef] [PubMed]
  92. Cimerman, N.G.; Cimerman, A. Pleurotus fruiting bodies contain the inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase—lovastatin. Exp. Mycol. 1995, 19, 1–6. [Google Scholar] [CrossRef]
  93. Zhao, S.; Rong, C.; Liu, Y.; Xu, F.; Wang, S.; Duan, C.; Chen, J.; Wu, X. Extraction of a soluble polysaccharide from Auricularia polytricha and evaluation of its anti-hypercholesterolemic effect in rats. Carbohydr. Polym. 2015, 122, 39–45. [Google Scholar] [CrossRef] [PubMed]
  94. Vitak, T.Y.; Wasser, S.P.; Nevo, E.; Sybirna, N.O. The effect of the medicinal mushrooms Agaricus brasiliensis and Ganoderma lucidum (Higher Basidiomycetes) on the erythron system in normal and streptozotocin-induced diabetic rats. Int. J. Med. Mushrooms 2015, 17, 277–286. [Google Scholar] [CrossRef] [PubMed]
  95. Yurkiv, B.; Wasser, S.P.; Nevo, E.; Sybirna, N.O. Antioxidant Effects of Medicinal Mushrooms Agaricus brasiliensis and Ganoderma lucidum (Higher Basidiomycetes): Evidence from Animal Studies. Int. J. Med. Mushrooms 2015, 17, 943–955. [Google Scholar] [CrossRef] [PubMed]
  96. Geng, X.; Tian, G.; Zhang, W.; Zhao, Y.; Zhao, L.; Wang, H.; Ng, T.B. A Tricholoma matsutake peptide with Angiotensin Converting Enzyme inhibitory and antioxidative activities and antihypertensive effects in spontaneously hypertensive rats. Sci. Rep. 2016, 6, 24130. [Google Scholar] [CrossRef] [PubMed]
  97. Liu, Y.; Chen, D.; You, Y.; Zeng, S.; Hu, Y.; Duan, X.; Liu, A.; Chen, H.; Hu, X.; Chen, S.; et al. Structural characterization and antidiabetic activity of a glucopyranose-rich heteropolysaccharide from Catathelasma ventricosum. Carbohydr. Polym. 2016, 149, 399–407. [Google Scholar] [CrossRef] [PubMed]
  98. Mao, D.; Ma, Y.; Geng, L.; Zhao, A.; Zheng, J.; Xu, C. Fermentation characteristics in stirred-tank reactor of exopolysaccharides with hypolipidemic activity produced by Pleurotus geesteranus 5#. An. Acad. Bras. Cienc. 2013, 85, 1473–1481. [Google Scholar]
  99. Lin, L.; Cui, F.; Zhang, J.; Gao, X.; Zhou, M.; Xu, N.; Zhao, H.; Liu, M.; Zhang, C.; Jia, L. Antioxidative and renoprotective effects of residue polysaccharides from Flammulina velutipes. Carbohydr. Polym. 2016, 146, 388–395. [Google Scholar] [CrossRef] [PubMed]
  100. Zhang, Z.; Lv, G.; He, W.; Shi, L.; Pan, H.; Fan, L. Effects of extraction methods on the antioxidant activities of polysaccharides obtained from Flammulina velutipes. Carbohydr. Polym. 2013, 98, 1524–1531. [Google Scholar] [CrossRef] [PubMed]
  101. Mohamad Ansor, N.; Abdullah, N.; Aminudin, N. Anti-angiotensin converting enzyme (ACE) proteins from mycelia of Ganoderma lucidum (Curtis) P. Karst. BMC Complement. Altern. Med. 2013, 13, 256. [Google Scholar] [CrossRef] [PubMed]
  102. Choi, H.S.; Cho, H.Y.; Yang, H.C.; Ra, K.S.; Suh, H.J. Angiotensin I-converting enzyme inhibitor from Grifola frondosa. Food Res. Int. 2001, 34, 177–182. [Google Scholar] [CrossRef]
  103. Hiwatashi, K.; Kosaka, Y.; Suzuki, N.; Hata, K.; Mukaiyama, T.; Sakamoto, K.; Shirakawa, H.; Komai, M. Yamabushitake mushroom (Hericium erinaceus) improved lipid metabolism in mice fed a high-fat diet. Biosci. Biotechnol. Biochem. 2010, 74, 1447–1451. [Google Scholar] [CrossRef] [PubMed]
  104. Yang, B.K.; Park, J.B.; Song, C.H. Hypolipidemic effect of an Exo-biopolymer produced from a submerged mycelial culture of Hericium erinaceus. Biosci. Biotechnol. Biochem. 2003, 67, 1292–1298. [Google Scholar] [CrossRef] [PubMed]
  105. Grdović, N.; Dinić, S.; Arambašić, J.; Mihailović, M.; Uskoković, A.; Marković, J.; Poznanović, G.; Vidović, S.; Zeković, Z.; Mujić, A.; et al. The protective effect of a mix of Lactarius deterrimus and Castanea sativa extracts on streptozotocin-induced oxidative stress and pancreatic β-cell death. Br. J. Nutr. 2012, 108, 1163–1176. [Google Scholar] [CrossRef] [PubMed]
  106. Yang, H.; Hwang, I.; Kim, S.; Hong, E.J.; Jeung, E.B. Lentinus edodes promotes fat removal in hypercholesterolemic mice. Exp. Ther. Med. 2013, 6, 1409–1413. [Google Scholar] [CrossRef] [PubMed]
  107. Yoon, K.N.; Lee, J.S.; Kim, H.Y.; Lee, K.R.; Shin, P.G.; Cheong, J.C.; Yoo, Y.B.; Alam, N.; Ha, T.M.; Lee, T.S. Appraisal of Antihyperlipidemic Activities of Lentinus lepideus in Hypercholesterolemic Rats. Mycobiology 2011, 39, 283–289. [Google Scholar] [CrossRef] [PubMed]
  108. Spim, S.R.; de Oliveira, B.G.; Leite, F.G.; Gerenutti, M.; Grotto, D. Effects of Lentinula edodes consumption on biochemical, hematologic and oxidative stress parameters in rats receiving high-fat diet. Eur. J. Nutr. 2017, 56, 2255–2264. [Google Scholar] [CrossRef] [PubMed]
  109. Yoon, K.N.; Alam, N.; Lee, J.S.; Cho, H.J.; Kim, H.Y.; Shim, M.J.; Lee, M.W.; Lee, T.S. Antihyperlipidemic effect of dietary Lentinus edodes on plasma, feces and hepatic tissues in hypercholesterolemic rats. Mycobiology 2011, 39, 96–102. [Google Scholar] [CrossRef] [PubMed]
  110. Kaur, A.; Dhingra, G.S.; Shri, R. Evaluation of carbohydrate metabolism inhibition by some species of medicinal mushrooms from India. Int. J. Med. Mushrooms 2015, 17, 351–360. [Google Scholar] [CrossRef] [PubMed]
  111. Koo, K.C.; Lee, D.H.; Kim, J.H.; Yu, H.E.; Park, J.S.; Lee, J.S. Production and characterization of antihypertensive angiotensin I-converting enzyme inhibitor from Pholiota adiposa. J. Microbiol. Biotechnol. 2006, 16, 757–763. [Google Scholar]
  112. Zheng, L.; Zhai, G.; Zhang, J.; Wang, L.; Ma, Z.; Jia, M.; Jia, L. Antihyperlipidemic and hepatoprotective activities of mycelia zinc polysaccharide from Pholiota nameko SW-02. Int. J. Biol. Macromol. 2014, 70, 523–529. [Google Scholar] [CrossRef] [PubMed]
  113. Li, N.; Li, L.; Fang, J.C.; Wong, J.H.; Ng, T.B.; Jiang, Y.; Wang, C.R.; Zhang, N.Y.; Wen, T.Y.; Qu, L.Y. Isolation and identification of a novel polysaccharide-peptide complex with antioxidant, antiproliferative and hypoglycaemic activities from the abalone mushroom. Biosci. Rep. 2012, 32, 221–228. [Google Scholar] [CrossRef] [PubMed]
  114. Zhang, J.; Meng, G.; Zhang, C.; Lin, L.; Xu, N.; Liu, M.; Cui, F.; Jia, L. The antioxidative effects of acidic-, alkalic-, and enzymatic-extractable mycelium zinc polysaccharides by Pleurotus djamor on liver and kidney of streptozocin-induced diabetic mice. BMC Complement. Altern. Med. 2015, 15, 440. [Google Scholar] [CrossRef] [PubMed]
  115. Alam, N.; Yoon, K.N.; Lee, J.S.; Cho, H.J.; Shim, M.J.; Lee, T.S. Dietary effect of Pleurotus eryngii on biochemical function and histology in hypercholesterolemic rats. Saudi J. Biol. Sci. 2011, 18, 403–409. [Google Scholar] [CrossRef] [PubMed]
  116. Alam, N.; Yoon, K.N.; Lee, T.S. Antihyperlipidemic activities of Pleurotus ferulae on biochemical and histological function in hypercholesterolemic rats. J. Res. Med. Sci. 2011, 16, 776–786. [Google Scholar] [PubMed]
  117. Ibadallah, B.X.; Abdullah, N.; Shuib, A.S. Identification of angiotensin-converting enzyme inhibitory proteins from mycelium of Pleurotus pulmonarius (oyster mushroom). Planta Med. 2015, 81, 123–129. [Google Scholar] [CrossRef] [PubMed]
  118. Yoon, K.N.; Alam, N.; Shim, M.J.; Lee, T.S. Hypolipidemic and antiatherogenesis effect of culinary-medicinal pink oyster mushroom, Pleurotus salmoneostramineus L. Vass. (higher Basidiomycetes), in hypercholesterolemic rats. Int. J. Med. Mushrooms 2012, 14, 27–36. [Google Scholar] [CrossRef] [PubMed]
  119. Wu, T.; Xu, B. Antidiabetic and antioxidant activities of eight medicinal mushroom species from China. Int. J. Med. Mushrooms 2015, 17, 129–140. [Google Scholar] [CrossRef] [PubMed]
  120. Hyoung Lee, D.; Ho Kim, J.; Sik Park, J.; Jun Choi, Y.; Soo Lee, J. Isolation and characterization of a novel angiotensin I-converting enzyme inhibitory peptide derived from the edible mushroom Tricholoma giganteum. Peptides 2004, 25, 621–627. [Google Scholar] [CrossRef] [PubMed]
  121. Bobek, P.; Ozdín, L.; Kuniak, L.; Hromadová, M. Regulation of cholesterol metabolism with dietary addition of oyster mushrooms (Pleurotus ostreatus) in rats with hypercholesterolemia. Cas Lek Cesk 1997, 136, 186–190. [Google Scholar] [PubMed]
  122. Yang, B.K.; Kim, G.N.; Jeong, Y.T.; Jeong, H.; Mehta, P.; Song, C.H. Hypoglycemic effects of exo-biopolymers produced by five different medicinal mushrooms in STZ-induced diabetic rats. Mycobiology 2008, 36, 45–49. [Google Scholar] [CrossRef] [PubMed]
  123. Yang, U.K.; Jeong, S.C.; Lee, H.J.; Sohn, D.H.; Song, C.H. Antidiabetic and hypolipidemic effects of Collybia confluens mycelia produced by submerged culture in streptozotocin—Diabetic rats. Arch. Pharmacol. Res. 2006, 29, 73–79. [Google Scholar] [CrossRef]
  124. Chen, X.; Wu, G.; Huang, Z. Structural analysis and antioxidant activities of polysaccharides from cultured Cordyceps militaris. Int. J. Biol. Macromol. 2013, 58, 18–22. [Google Scholar] [CrossRef] [PubMed]
  125. Yeh, M.Y.; Ko, W.C.; Lin, L.Y. Hypolipidemic and antioxidant activity of enoki mushrooms (Flammulina velutipes). BioMed Res. Int. 2014, 2014, 352385. [Google Scholar] [CrossRef] [PubMed]
  126. Zhang, H.N.; Lin, Z.B. Hypoglycemic effect of Ganoderma lucidum polysaccharides. Acta Pharmacol. Sin. 2004, 25, 191–195. [Google Scholar] [PubMed]
  127. Li, F.; Zhang, Y.; Zhong, Z. Antihyperglycemic effect of Ganoderma lucidum polysaccharides on streptozotocin-induced diabetic mice. Int. J. Mol. Sci. 2011, 12, 6135–6145. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  128. Zheng, J.; Yang, B.; Yu, Y.; Chen, Q.; Huang, T.; Li, D. Ganoderma lucidum polysaccharides exert anti-hyperglycemic effect on streptozotocin-induced diabetic rats through affecting β-cells. Comb. Chem. High Throughput Screen 2012, 15, 542–550. [Google Scholar] [CrossRef] [PubMed]
  129. Yang, B.K.; Kim, D.H.; Jeong, S.C.; Das, S.; Choi, Y.S.; Shin, J.S.; Lee, S.C.; Song, C.H. Hypoglycemic effect of a Lentinus edodes exo-polymer produced from a submerged mycelial culture. Biosci. Biotechnol. Biochem. 2002, 66, 937–942. [Google Scholar] [CrossRef] [PubMed]
  130. Hwang, H.J.; Kim, S.W.; Lim, J.M.; Joo, J.H.; Kim, H.O.; Kim, H.M.; Yun, J.W. Hypoglycemic effect of crude exopolysaccharides produced by a medicinal mushroom Phellinus baumii in streptozotocin-induced diabetic rats. Life Sci. 2005, 76, 3069–3080. [Google Scholar] [CrossRef] [PubMed]
  131. Rony, K.A.; Ajith, T.A.; Mathew, J.; Janardhanan, K.K. The medicinal cracked-cap polypore mushroom Phellinus rimosus (higher Basidiomycetes) attenuates alloxan-induced hyperglycemia and oxidative stress in rats. Int. J. Med. Mushrooms 2013, 15, 287–300. [Google Scholar] [CrossRef] [PubMed]
  132. Rony, K.A.; Ajith, T.A.; Janardhanan, K.K. Hypoglycemic and hypolipidemic effects of the cracked-cap medicinal mushroom Phellinus rimosus (Higher Basidiomycetes) in streptozotocin-induced diabetic rats. Int. J. Med. Mushrooms 2015, 17, 521–531. [Google Scholar] [CrossRef] [PubMed]
  133. Cho, E.J.; Hwang, H.J.; Kim, S.W.; Oh, J.Y.; Baek, Y.M.; Choi, J.W.; Bae, S.H.; Yun, J.W. Hypoglycemic effects of exopolysaccharides produced by mycelial cultures of two different mushrooms Tremella fuciformis and Phellinus baumii in ob/ob mice. Appl. Microbiol. Biotechnol. 2007, 75, 1257–1265. [Google Scholar] [CrossRef] [PubMed]
  134. Li, H.; Lee, H.S.; Kim, S.H.; Moon, B.; Lee, C. Antioxidant and anti-inflammatory activities of methanol extracts of Tremella fuciformis and its major phenolic acids. J. Food Sci. 2014, 79, C460–C468. [Google Scholar] [CrossRef] [PubMed]
  135. Yang, B.K.; Jung, Y.S.; Song, C.H. Hypoglycemic effects of Ganoderma applanatum and Collybia confluens exo-polymers in streptozotocin-induced diabetic rats. Phytother. Res. 2007, 21, 1066–1069. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Pathophysiology of obesity and energy homeostasis—Melanin-concentrating hormone (MCH) is a peptide hormone, synthesized by the neurons of the hypothalamus, which normally stimulate food intake. These neurons are arbitrated by POMC as well as NPY/AGRP in an arcuate nucleus. Leptin and insulin are peptide hormones that activate POMC while inhibiting NPY/AGRP, consequently reduces body weight through energy expenditure or lipolysis and release free fatty acids (FFA). In contrast, the hunger hormone, ghrelin provokes NPY/AGRP and enhances body weight through the intake of food. MCH neurons are impeded by POMC cells, however, NPY/AGRP neurons are known to have an antagonist effect. Weight loss reduces insulin and leptin amounts in the blood while increasing ghrelin levels. This response is regulated by the arcuate nucleus (triggering of NPY/AGRP and impeding of POMC) that ultimately activates MCH neurons.
Figure 1. Pathophysiology of obesity and energy homeostasis—Melanin-concentrating hormone (MCH) is a peptide hormone, synthesized by the neurons of the hypothalamus, which normally stimulate food intake. These neurons are arbitrated by POMC as well as NPY/AGRP in an arcuate nucleus. Leptin and insulin are peptide hormones that activate POMC while inhibiting NPY/AGRP, consequently reduces body weight through energy expenditure or lipolysis and release free fatty acids (FFA). In contrast, the hunger hormone, ghrelin provokes NPY/AGRP and enhances body weight through the intake of food. MCH neurons are impeded by POMC cells, however, NPY/AGRP neurons are known to have an antagonist effect. Weight loss reduces insulin and leptin amounts in the blood while increasing ghrelin levels. This response is regulated by the arcuate nucleus (triggering of NPY/AGRP and impeding of POMC) that ultimately activates MCH neurons.
Molecules 23 02880 g001
Figure 2. Physiological disorders related to obesity and its impact on human health. Endometrial cancer: Obesity elevates the threat of endometrial cancer via endocrine pathways. Elevated adiposity provokes aromatase action, leading to augmented estrogen in postmenopausal women. Estrogens generally elevate endometrial cell propagation and stimulating the production of IGF-binding protein 1 (IGF1)-cause endometrial cancer. Tumor development: Adipocyte normally synthesizes aromatase and 17β-hydroxysteroid dehydrogenase (17β-HSD). In obese persons, there is elevated transformation of the androgens Δ4-androstenedione (Δ4A) and testosterone (T) into the estrogens, oestrone (E1) and oestradiol (E2), respectively, by an enzyme, aromatase. 17β-HSD catalyze the Δ4A and E1 (less biologically active hormones) into the T and E2 (more active hormones), respectively. The circulating levels of sex-hormone-binding globulin aids to elevate the amounts of E2 and T that can readily diffuse across to target cells through binding with estrogen and androgen receptors. Ultimately, they inhibit apoptosis and promote cellular proliferation in the breast epithelium and endometrium. Diabetes: obesity leads to hyperinsulinemia and diabetes, which in turn produce AGE cause pro-inflammatory state by NF-χB, protein kinase, and intracellular adhesion molecules. Based on the reduction of NO and more leucocytes infiltration on the vessels cause endothelial and microvascular dysfunction, which influenced by oxidative stress (ROS), eventually cause atherosclerosis and hypertension. Carbohydrate and lipid metabolism: Excess glucose and fatty acid oxidation leads to lipid peroxidation, which facilitates lipoprotein toxicity and enhances the rate of hypertension in the blood vessels.
Figure 2. Physiological disorders related to obesity and its impact on human health. Endometrial cancer: Obesity elevates the threat of endometrial cancer via endocrine pathways. Elevated adiposity provokes aromatase action, leading to augmented estrogen in postmenopausal women. Estrogens generally elevate endometrial cell propagation and stimulating the production of IGF-binding protein 1 (IGF1)-cause endometrial cancer. Tumor development: Adipocyte normally synthesizes aromatase and 17β-hydroxysteroid dehydrogenase (17β-HSD). In obese persons, there is elevated transformation of the androgens Δ4-androstenedione (Δ4A) and testosterone (T) into the estrogens, oestrone (E1) and oestradiol (E2), respectively, by an enzyme, aromatase. 17β-HSD catalyze the Δ4A and E1 (less biologically active hormones) into the T and E2 (more active hormones), respectively. The circulating levels of sex-hormone-binding globulin aids to elevate the amounts of E2 and T that can readily diffuse across to target cells through binding with estrogen and androgen receptors. Ultimately, they inhibit apoptosis and promote cellular proliferation in the breast epithelium and endometrium. Diabetes: obesity leads to hyperinsulinemia and diabetes, which in turn produce AGE cause pro-inflammatory state by NF-χB, protein kinase, and intracellular adhesion molecules. Based on the reduction of NO and more leucocytes infiltration on the vessels cause endothelial and microvascular dysfunction, which influenced by oxidative stress (ROS), eventually cause atherosclerosis and hypertension. Carbohydrate and lipid metabolism: Excess glucose and fatty acid oxidation leads to lipid peroxidation, which facilitates lipoprotein toxicity and enhances the rate of hypertension in the blood vessels.
Molecules 23 02880 g002
Figure 3. Antihypertensive effect of mushrooms—Mushrooms are found to be Angiotensin Converting Enzyme (ACE) inhibitors, which help to reduce hypertension by constraining ACE. This enzyme is accountable for transforming the inactive protein Ang I into the active Ang II. The renin-angiotensin system–angiotensin II has a multifaceted range of effects on the maintenance of blood pressure and this impact elevates sodium and water retention through the release of aldosterone.
Figure 3. Antihypertensive effect of mushrooms—Mushrooms are found to be Angiotensin Converting Enzyme (ACE) inhibitors, which help to reduce hypertension by constraining ACE. This enzyme is accountable for transforming the inactive protein Ang I into the active Ang II. The renin-angiotensin system–angiotensin II has a multifaceted range of effects on the maintenance of blood pressure and this impact elevates sodium and water retention through the release of aldosterone.
Molecules 23 02880 g003
Figure 4. Effect of edible and medicinal mushrooms on dyslipidemia.
Figure 4. Effect of edible and medicinal mushrooms on dyslipidemia.
Molecules 23 02880 g004
Table 1. In vitro and in vivo actions of edible and medicinal mushrooms and their anti-obesity potential.
Table 1. In vitro and in vivo actions of edible and medicinal mushrooms and their anti-obesity potential.
Edible/Medicinal MushroomBotanical NameStudy Model/MethodsBioactive CompoundsReferences
EdibleAgaricus campestrisHypercholesterolemic diet and STZ induced rats-plasma glucose, TG, TC, ALT, AST and LDLVitamin C, D, B12, folates, and polyphenols[63]
EdibleAgaricus bisporusHigh-fat diet in rats-serum cholesterol and hepatic LDL receptor mRNAFibers [32]
Hypertensive rats-Angiotensin I-Converting Enzyme assayOligopeptide [30]
EdibleAgaricus brasiliensisSTZ-induced diabetic rats-plasma glucose, TG, TC, glycated hemoglobin, TBARSPolyphenols and flavonoids[94,95]
Hypertensive rats-Angiotensin I-Converting Enzyme assayOligopeptide [27]
EdibleBoletus bicolorHypertensive rats-Angiotensin I-Converting Enzyme assayOligopeptide [96]
EdibleLeucopaxillus tricolorHypertensive rats-Angiotensin I-Converting Enzyme assayOligopeptide [29]
EdibleCatathelasma ventricosumSTZ induced diabetic rats-plasma glucose, total TC, TGHeteropolysaccharide[97]
EdiblePleurotus geesteranusSTZ induced diabetic rats-plasma glucose, total TC, TGPolysaccharides[98]
EdibleFlammulina velutipesSTZ-induced diabetic rats-SOD, GSH-Px, CAT, MDA, ALT, AST, BUN, CRE, TC, LDL-C and HDL-CPolysaccharides[99]
In vitro-DPPH free radical & Hydroxy radical scavenging, in vitro α-glycosidase, aldose reductase inhibitory assaysPolysaccharides[100]
EdibleG. lucidumHypertensive rats-ACE assayOligopeptide [101]
EdibleGloeostereum incarnatumHypertensive rats-ACE assayOligopeptide [29]
EdibleGrifola frondosaHypertensive rats-ACE assayOligopeptide [29]
Hypertensive rats-ACE assayOligopeptide [102]
EdibleHericium erinaceusC57BL/6J mice model-serum and hepatic TG levelsFlavonoids [103]
Hyperlipidemic rats-plasma total cholesterol, LDL, HDL, cholesterol, triglyceride, phospholipid, atherogenic index, and hepatic HMG-CoA reductaseExo-polymer[104]
EdibleHypsizygus marmoreusHypertensive rats-ACE assayOligopeptide[84]
EdibleLactarius deterrimusSTZ-induced diabetic rats-plasma glucose, TG, glycated hemoglobin, glycated serum protein, and AGE, SOD, CAT, GSH levelsPolyphenols and flavonoids[105]
EdibleLentinula edodesHigh-fat diet in rats-TG, TC, LDL, cholesterol 7-α-hydroxylase 1Lentinan KS-2[106]
High-fat diet in rats-TG, TC, LDL, total lipids, phospholipids, LDL/HDL ratio, BIL, CRE, Urea, BUN, Uric acid, Total protein, Na, Ca, Cl, K, albumin, P, MgLentinan KS-2[107]
High-fat diet in rabbits-TC, histological, immunohistochemical and morphometrically analysisLentinan KS-2[8]
High-fat diet in rats-TG, TC, ALT, AST, Urea, glucose, malondialdehydeLentinan KS-2[108]
EdibleLentinus lepideusHigh-fat diet in rats-TG, TC, LDL, total lipids, phospholipids, LDL/HDL ratio, BIL, CRE, Urea, BUN, Uric acid, Total protein, Na, Ca, Cl, K, albumin, P, MgLentinan KS-2, flavonoids[109]
EdibleLenzites elegansin vitro enzymatic starch digestion assayPolyphenols and flavonoids[110]
EdibleMorchella vulgarisHypertensive rats-ACE assayOligopeptide[29]
EdibleOudemansiella radicataHypertensive rats-ACE assayOligopeptide[29]
EdiblePholiota adiposeHypertensive rats-ACE assayOligopeptide[111]
EdiblePholiota nameko SW-02mice hyperlipidemic models-blood lipid levels (TC, TG, HDL-C, LDL-C, and VLDL-C), liver lipid levels (TC and TG) and antioxidant status (SOD, T-AOC, MDA, and LPO)Mycelia zinc polysaccharide[112]
EdiblePleurotus abalonusDiabetic mice-Inhibition of the proliferation of hepatoma HepG2 cells and breast cancer MCF7 cells, antioxidant activity in erythrocyte hemolysis, blood glucose and TGPolysaccharide-peptide complex LB-1b[113]
EdiblePleurotus cornucopiaeHypertensive rats-Angiotensin I-Converting Enzyme assayOligopeptide[87]
EdiblePleurotus cystidiosus O.K. MillerHypertensive rats-Angiotensin I-Converting Enzyme assayOligopeptide[85]
EdiblePleurotus djamorSTZ-induced diabetic rats-SOD, GSH-Px, CAT, MDA, ALT, AST, BUN, CRE, TC, LDL-C and HDL-CMycelium zinc polysaccharides[114]
EdiblePleurotus eryngiiHigh-fat diet in rats-TG, TC, LDL, total lipids, phospholipids, LDL/HDL ratio, BIL, CRE, Urea, BUN, Uric acid, Total protein, Na, Ca, Cl, K, albumin, P, MgPolysaccharides[115]
EdiblePleurotus ferulaeHigh-fat diet in rats-TG, TC, LDL, total lipids, phospholipids, LDL/HDL ratio, BIL, CRE, Urea, BUN, Uric acid, Total protein, Na, Ca, Cl, K, albumin, P, MgPolysaccharides[116]
EdiblePleurotus ostreatusHigh-fat diet in rats-TG, TC, LDL, total lipids, phospholipids, LDL/HDL ratio, BIL, CRE, Urea, BUN, Uric acid, Total protein, Na, Ca, Cl, K, albumin, P, MgPolysaccharides[86]
EdiblePleurotus pulmonariusHypertensive rats-Angiotensin I-Converting Enzyme assayOligopeptide[117]
EdiblePleurotus salmoneostramineus L. VassHigh-fat diet in rats-TG, TC, LDL, total lipids, phospholipids, LDL/HDL ratio, BIL, CRE, Urea, BUN, Uric acid, Total protein, Na, Ca, Cl, K, albumin, P, MgPolysaccharides[118]
EdiblePleurotus tuber-regiumOb diabetic rats-TC, TG, LDL, HDL, and PPAR-α mRNA expressionPolysaccharides [72]
EdibleRamaria botrytoidesHypertensive rats-ACE assayOligopeptide[29]
EdibleRussula aerugineaHypertensive rats-ACE assayOligopeptide[29]
EdibleTremella fuciformisin vitro α-glycosidase, aldose reductase inhibitory assays, DPPH free radical scavengingPolyphenols and flavonoids[119]
EdibleTricholoma giganteumHypertensive rats-ACE assayOligopeptide[120]
EdibleTricholoma matsutakeHypertensive rats-ACE assayOligopeptide[96]
EdibleTuber micheliHypertensive rats-ACE assayOligopeptide[29]
EdiblePleurotus ostreatusTC content in serum, lipoproteins in the liver, and HMG-CoA reductase in liver microsomesPolysaccharides[121]
Inhibition of HMG CoA reductase-lovastatinPolysaccharides[92]
EdibleAdiantum capillus-veneris L.High cholesterol diet fed Wistar rats-Pancreatic triacylglycerol lipase and α-amylase/α-glucosidase, OGTT, TC, TGPolyphenols[9]
EdibleAster spathulifolius MaximHigh-fat diet fed Wistar rats-body weight gain, visceral fat pad weights, serum lipid levels, as well as hepatic lipid levels, numbers of lipid droplets, expression of fat intake-related gene ACC2 and lipogenesis-related genes (e.g., SREBP-1c, ACC1, FAS, SCD1, GPATR, AGPAT, and DGAT), fatty acid oxidation and thermogenesis-related genes (e.g., PPAR-α, ACO, CPT1, UCP2, and UCP3), phosphorylated AMPKα, phosphorylated ACCPolysaccharides[3]
EdibleKluyveromyces marxianusThe high-fat diet fed Wistar rats-TC, TG, HDL-C, LDL-C, levels in the serum and liver, atherogenic indexPolysaccharides[91]
Edible and MedicinalCollybia peronata, Ganoderma australe, Ganoderma lingzhi, Heterobasidion linzhiense, Heterobasidion linzhiense, Inocybe sp., Inonotus andersonii, Lactarius hatsudake, Lenzites betulina, Panellus sp., Phellinus conchatus, Phellinus gilvus, Phlebia tremellosa, Postia stiptica, Rigidoporus sp., Trametes versicolor, Tricholoma caligatumACE Inhibitory AssayPolyphenol[90]
MedicinalArmillariella melleaSTZ-induced diabetic rats-plasma glucose, TG, TC, ALT, ASTexo-biopolymers[122]
MedicinalAuricularia auricula-judaeHigh-fat diet in mice-phospholipids, liver enzymes, TG, glycerol, glycerol-3-phosphate dehydrogenasePhenolic compound[88]
MedicinalCollybia confluensSTZ induced animal model-plasma glucose, total TC, TG, ALT, ASTExo-polymer[123]
MedicinalCordyceps militarisIn vitro-Superoxide anion, DPPH free radical & Hydroxy radical scavenging, In vitro-HMG-CoA reductase and α-glucosidasePolysaccharides[124]
mice hyperlipidemic models-blood lipid levels (TC, TG, HDL-C, LDL-C, and VLDL-C), liver lipid levels (TC and TG) and antioxidant status (SOD, T-AOC, MDA, and LPO)Polysaccharides[73]
MedicinalCordyceps sinensisSTZ-induced diabetic rats-plasma glucose, TG, TC, ALT, ASTexo-biopolymers[122]
MedicinalCoriolus versicolorSTZ-induced diabetic rats-plasma glucose, TG, TC, ALT, ASTexo-biopolymers[122]
MedicinalFlammulina velutipesHigh-fat diet in rats-TC, LDL, body weight, food intake, liver weight, cecum weight, cecum pH, Cecal acetic acid, butyric acid, and total SCFAFibers[89]
High-fat diet in male hamsters-TG, TC, LDL, total lipids, phospholipids, LDL/HDL ratioDietary fiber, polysaccharide, and mycosterol,[125]
MedicinalFomes fomentariusSTZ-induced diabetic rats-plasma glucose, TG, TC, ALT, ASTExo-biopolymers[89]
MedicinalGanoderma leucocontextumIn vitro-HMG-CoA reductase and α-glucosidaseLanostane (Triterpenes)[65]
MedicinalGanoderma lucidumSTZ-induced diabetic rats-plasma glucose, TC, TG, glycated hemoglobin, TBARSPolysaccharides[94,95]
STZ-induced diabetic rats-plasma glucose, TG, TC, NO, SOD, CAT, GPxPolysaccharides[126,127,128]
in vitro α-glycosidase, aldose reductase inhibitory assays, DPPH free radical scavengingPolyphenols and flavonoids[119]
MedicinalGanoderma philippiiin vitro enzymatic starch digestion assayAppanoxidic acid A[110]
MedicinalGrifola frondosaHigh-fat diet in rats-TC, LDL, body weight, food intake, liver weight, cecum weight, cecum pH, Cecal acetic acid, butyric acid, and total short-chain fatty acidFiber[89]
MedicinalLentinus edodesSTZ induced animal model-plasma glucose, total cholesterol, and triglycerideExo-polymer[129]
High-fat diet in rats-TC, LDL, body weight, food intake, liver weight, cecum weight, cecum pH, Cecal acetic acid, butyric acid, and total short-chain fatty acidFibers[89]
MedicinalPaecilomyces japonicaSTZ-induced diabetic rats-plasma glucose, TG, TC, ALT, ASTexo-biopolymers[122]
MedicinalPhellinus baumiiSTZ induced diabetic rats-plasma glucose, TG, TC, ALT, ASTHeteropolysaccharides and two proteoglycans[130]
MedicinalPhellinus rimosusAlloxan-induced diabetic rats-plasma glucose, OGTT, TC, TG, SOD, CAT, GPx, and GSHPolysaccharides[131]
STZ-induced diabetic rats-plasma glucose, lipid profile, ALT, AST, serum insulin, liver glycogenPolysaccharides [132]
MedicinalRigidoporus ulmariusin vitro enzymatic starch digestion assayPolysaccharides[110]
MedicinalTremella fuciformisob/ob mice-Plasma glucose, OGTT, TGExopolysaccarides[133]
In vitro-ABTS radical scavenging activity, DPPH radical scavenging activity, LDL oxidation; NO synthase expression in RAW 264.7 cellsPolyphenols and flavonoids[134]
MedicinalGanoderma applanatum and Collybia confluensSTZ-induced diabetic rats-Plasma glucose, TC, TGExo-polymer[135]
MedicinalAuricularia polytrichaSerum total lipids and TCPolysaccharides[93]
MedicinalPleurotus sajor-caju (Fr.) SingerC57BL/6J mice fed on a high-fat diet-body weight, serum lipid, and liver enzymes, protein carbonyl and lipid hydroperoxide levels, enzymic antioxidants (SOD, CAT, and GPx) activities, Expression of hormone-sensitive lipase, adipose triglyceride lipase, peroxisome proliferator-activated receptor gamma, sterol regulatory binding protein-1c, and lipoprotein lipaseβ-glucan[1]
Abbreviations: 17β-HSD: 17β-hydroxysteroid dehydrogenase; ACC1: acetyl-CoA carboxylase 1; ACE: angiotensin converting enzyme; ACO: 1-aminocyclopropane-1-carboxylate oxidase; AGE: advanced glycation end products; AGPAT: 1-acylglycerol-3-phosphate O-acyltransferase 1; AgRP: agouti-related peptide; ALT: alanine transaminase; AMPK: 5′ adenosine monophosphate-activated protein kinase; Ang-I: angiotensin I; Ang-II: angiotensin II; AST: aspartate transaminase; AT-1: angiotensin II type 1 receptor; BMI: body mass index; BMR: basal metabolic rate; BUN: blood urea nitrogen; Ca: calcium; CAT: catalase; Cl: chloride; CNS: central nervous system; CPT1: carnitine Palmitoyltransferase 1A; CRE: creatinine; CRP: c-reactive protein; CVD: cardiovascular diseases; DGAT: diacylglycerol O-Acyltransferase 1; DPPH: 2,2-diphenyl-1-picrylhydrazyl; E1: estrone; E2: estradiol; FFA: free fatty acids; GPATR: glycerol-3-phosphate acyltransferase; GSH: glutathione; GSH-Px: glutathione peroxidase; HDL: high density lipoprotein; HFD: high fat diet; HMG-CoA: β-hydroxy, β methyl glutaryl COA; ICAM: Intercellular Adhesion Molecule; IGF1: IGF binding protein 1; IL-1: interleukin 1; IL-6: interleukin 6; K: potassium; LDL: low density lipoprotein; LPO: lipid peroxidation; MAPK: mitogen-activated protein kinases; MCH: melanin concentrating hormone; MDA: melondialdehyde; Mg: magnesium; mRNA: messenger ribonucleic acids; Na: sodium; NF-χB: nuclear factor kappa B; NO: nitric oxide; NPY: neuropeptide Y; OGTT: oral glucose tolerance test; P: phosphorus; POMC: pro-opiomelanocortin; PPAR-α: peroxisome proliferator-activated receptor alpha; PUFA: poly unsaturated fatty acids; RAS: renin-angiotensin-aldosterone system; ROS: reactive oxygen species; SCD1: stearoyl-CoA desaturase 1; SCFA: short chain fatty acids; SCFA: short chain fatty acids; SOD: superoxide dismutase; SREBP-1c: sterol regulatory element-binding transcription factor 1; STZ: streptozotocin; T-AOC: total antioxidant capacity; TBARS: thiobarbituric acid reactive substances; TC: total cholesterol; TG: triglycerides; TNF-α: tumour necrosis factor-α; UCP2: mitochondrial uncoupling proteins 2; UCP3: mitochondrial uncoupling proteins 3; VCAM: vascular cell adhesion molecule; VLDL: very low density lipoprotein; Δ4A: Δ4-androstenedione.

Share and Cite

MDPI and ACS Style

Ganesan, K.; Xu, B. Anti-Obesity Effects of Medicinal and Edible Mushrooms. Molecules 2018, 23, 2880.

AMA Style

Ganesan K, Xu B. Anti-Obesity Effects of Medicinal and Edible Mushrooms. Molecules. 2018; 23(11):2880.

Chicago/Turabian Style

Ganesan, Kumar, and Baojun Xu. 2018. "Anti-Obesity Effects of Medicinal and Edible Mushrooms" Molecules 23, no. 11: 2880.

Article Metrics

Back to TopTop